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ABSTRACT 
 
 
Up to 80% of patients with chronic kidney disease (CKD) have some degree of mineral 
and bone disorder (MBD), which is associated with higher morbidity and mortality, specifically 
from cardiovascular causes. Despite the pharmacological treatment for MBD, its prevalence 
remains high, especially for patients with kidney failure undergoing chronic hemodialysis (HD) 
treatment. Restriction of dietary phosphorus along with phosphate binders represents an 
important part of the treatment of MBD. However, due to this restriction along with a potassium-
restricted diet, HD patients limit a variety of foods that contain dietary fiber. The 
supplementation of dietary fiber, specifically fermentable fiber, has been explored in other 
clinical populations with MBD, such as female adolescents and postmenopausal women. While it 
is known that this supplementation leads to a higher production of short-chain fatty acids (SCFA) 
by the gut microbiota and an effect on the absorption of calcium and magnesium, this mechanism 
remains unexplored in HD patients.  The supplementation of inulin, a fermentable fiber, 
represents a feasible and low-cost co-adjuvant therapy for the treatment of MBD in HD patients. 
Therefore, the objective of this dissertation is to examine the effects of the supplementation of 
inulin on bone and mineral metabolism and the gut microbiota in HD patients.  
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CHAPTER 1 
INTRODUCTION  
According to the United States Renal Data System (USRDS), up to 2014 the overall 
prevalence of chronic kidney disease (CKD) was 14% of adults, which has remained stable since 
2004.1 Once patient’s glomerular filtration rate (GFR) reaches less than 15ml/min/1.73m2, it is 
considered end-stage renal disease (ESRD), which represents a non-reversible damage to the 
kidney where there is a need of a renal replacement therapy or a kidney transplant. In the United 
States, the most common form of renal replacement therapy is hemodialysis (HD), used in 
almost 64% of the prevalent ESRD patients.1 One of the most prevalent problems in ESRD 
patients undergoing chronic HD treatment is mineral and bone disorder (MBD), which can be 
seen as early as CKD stage 2, where the kidney function has declined by 10-40%.1,2 The 
diagnosis of MBD includes at least one of the following: a) laboratory abnormalities (e.g., 
hypocalcemia, hyperphosphatemia, secondary hyperparathyroidism, low concentrations vitamin 
D [calcidiol and/or calcitriol]) and high fibroblast growth factor-23 (FGF-23); b) bone 
abnormalities (e.g., altered turnover, volume and mineralization); and c) extra-skeletal 
calcifications (e.g., vascular calcification).3 The disruption in bone and mineral homeostasis 
critically affects the bone structure and function by altering bone turnover and can lead to a 
negative bone balance (high bone resorption and normal-to-low bone formation) in this clinical 
population.4 Up to 80% of CKD patients have some degree of MBD, which is associated with 
increased risk of fractures, cardiovascular disease, hospitalization, and mortality and lower 
quality of life.5,6  
Despite the pharmacological treatment for MBD, which include phosphate binders, 
calcimimetics, and vitamin D analogs, the prevalence of MBD remains high, especially for 
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patients with kidney failure undergoing chronic HD treatment. Restriction of dietary phosphorus 
along with phosphate binders represents a main part of the treatment of MBD.7 However, due to 
this dietary phosphorus restriction along with a potassium-restricted diet, HD patients limit 
intake of certain food groups, such as fruits, vegetables, legumes, whole grains, nuts, and 
legumes. These food groups, however, are also good sources of fiber.8 The supplementation of 
dietary fiber, specifically fermentable fiber, has been explored in other clinical populations with 
MBD, such as female adolescents and postmenopausal women.9–12 While it is known that this 
supplementation leads to a higher production of short-chain fatty acids (SCFA) by the gut 
microbiota and an effect on the absorption of minerals, especially calcium and magnesium, this 
mechanism remains unexplored in HD patients.  The supplementation of inulin, a fermentable 
fiber, represents a feasible and low-cost co-adjuvant therapy for the treatment of MBD in HD 
patients. Therefore, the objective of this trial is to assess the effects of a four-week 
supplementation with inulin on markers of MBD. Additionally, as secondary outcomes, the 
effects of the supplementation of inulin on the gut microbiota will be assessed.  
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CHAPTER 2  
 LITERATURE REVIEW: MODIFIED NUTRITIONAL RECOMMENDATIONS TO 
IMPROVE DIETARY PATTERNS AND OUTCOMES IN HEMODIALYSIS PATIENTS  
Introduction 
The renal diet has traditionally been one of the most complex medical nutrition therapies 
to teach, understand, and implement. End stage renal disease (ESRD) medical nutrition therapy 
dictates that patients shift their nutrition goals from standard dietary recommendations to a 
pattern that manages levels of circulating waste products and minerals between dialysis 
treatments. This is especially true for patients undergoing chronic hemodialysis (HD) treatment 
due to the 48-72h span between treatments. Specifically, patients are instructed to limit fruits, 
vegetables, nuts, legumes, dairy, and whole grains because of both phosphorus and potassium 
(K+) concerns.13 These dietary restrictions are even more challenging due to elevated protein and 
energy needs. Further, HD patients are often encouraged to decrease fluid intake to control 
interdialytic weight gain (IDWG).14,15 These restrictions can result in frustration, lack of 
autonomy, and the perception that there is nothing left to eat.13,16 In some cases, this can result in 
a disregard for the nutrition recommendations altogether and a reliance on processed, 
convenience, and restaurant foods.17,18 These choices can further exacerbate complications and 
comorbidities associated with ESRD including cardiovascular (CV) disease, poor glycemic 
control, large IDWG, continued struggles with phosphorus and K+ regulation, with a potentially 
confounding low intake of other vitamins, minerals, antioxidants, and dietary fiber.8,19,20 Indeed, 
it appears that standard dietary prescription for HD patients may be doing more harm than good.  
Reprinted from Journal of Renal Nutrition, Volume 27, Issue 1, Pages 62-70, Authors: Biruete 
A, Jeong JH, Barnes JL, and Wilund KR, Title: Modified Dietary Recommendations to Improve 
Dietary Patterns and Outcomes in Hemodialysis Patients  
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There has been a slowly emerging discussion of ‘liberalizing’ the diet prescription in an 
effort to decrease the total sodium and phosphorus additive load while inducing a corresponding 
increase in fiber, antioxidants, and phytochemicals, resulting in an overall improved dietary 
profile, particularly for CV health.  
 Considering the burden associated with ESRD and HD treatment, every effort must be 
made to support quality of life and patient dietary options. It is possible that the traditional ESRD 
medical nutrition therapy may be liberalized in order to afford patients greater choices and 
ultimately improved outcomes. The objective of this review is to assess the evidence in support 
of a renal diet focused on reducing the intake of sodium and inorganic phosphorus. In addition, 
the limited evidence for restricting dietary K+ intake is summarized.    
Sodium 
Sodium is the main cation in the extracellular space and a key contributor to plasma 
osmolality.21 In HD patients, increases in plasma osmolality may occur due to excessive dietary 
sodium intake or from treatment-related factors, such as the use of high-sodium dialysate 
solutions or hypertonic saline infusion used for the prevention of cramping and intradialytic 
hypotension. Each of these sodium sources may increase thirst and have been associated with 
higher IDWG, pre-dialysis systolic blood pressure (BP) and chronic fluid overload,22 which are 
in turn associated with acute and chronic CV complications and mortality.23,24 In order to prevent 
the aforementioned complications, dietary sodium restriction is advised to HD patients.  
Dietary sodium intake and clinical outcomes in HD patients 
Guidelines from the Kidney Disease Outcomes Quality Initiative (KDOQI) recommend to 
limit dietary sodium.15 However, the expert panel did not recommend a specific dietary sodium 
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prescription and called for the assessment of an ideal dietary sodium intake for HD patients, 
although previous guidelines recommended a dietary sodium intake below 2000mg/day.14 
Surprisingly, there is little data assessing the relationship between dietary sodium intake and 
clinical outcomes in HD patients. Furthermore, most studies in the United States have been 
observational and based on self-reported intake, which may underestimate dietary intake due to 
underreport and variability of sodium content of foods.25,26 In a post-hoc analysis of the 
Hemodialysis (HEMO) Study, McCausland et al.23 reported a mean sodium intake of 2240±1050 
mg/day, which was higher in younger, male, non-black participants with longer dialysis vintage. 
Moreover, there was a positive association between dietary sodium intake and mortality risk. 
Interestingly, they did not find an association between dietary sodium intake and BP. In a cohort 
of 122 HD patients, Clark-Cutaia et al.27 reported a mean dietary sodium intake of 2,346±904 
mg/day and found that younger participants had higher dietary sodium intakes, elevated IDWG, 
and lower adherence to dietary sodium restriction.  
Evidence of potential benefits of dietary sodium restriction in HD patients 
It has long been recognized that hypertension and related CV co-morbidities can be 
controlled in many HD patients through non-pharmacological means. Dietary sodium restriction 
in conjunction with persistent ultrafiltration can limit extracellular volume expansion and 
hypertension in HD patients, without the need of antihypertensive medications.28 The 
contributions of a sodium-restricted diet as a component of a comprehensive volume control 
strategy has been highlighted by data from the HD populations in Tassin, France, and Izmir, 
Turkey. For over 40 years, HD clinics in Tassin have used a protocol to control hypertension that 
includes the use of sodium-restricted diets in combination with longer dialysis sessions (up to 
8h).29 Interestingly, they have reported controlled BP in 90% of their patients without the use of 
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antihypertensive medications, as well as lower mortality rates.30 HD clinics in Izmir have used a 
similar protocol, though with shorter HD sessions (~4h), which may be more applicable to the 
United States.31 In a retrospective cross-sectional study, Kayikcioglu et al.24 compared CV 
parameters in patients at two HD centers that managed BP using different protocols. The first 
center controlled BP without the use of antihypertensive medications, primarily using dietary 
sodium-restriction (< 5g of salt, or 1,950mg of sodium/day) in conjunction with intensive 
ultrafiltration, while the second clinic controlled BP using antihypertensive medications. Patients 
relying on sodium-restriction and enhanced ultrafiltration had lower IDWG, lower left-
ventricular mass index, better systolic and diastolic function and higher serum albumin. 
Furthermore, only 7% of patients were using antihypertensive medications vs. 42% in the clinic 
utilizing standard BP control practices.24 In the United States, the application of Izmir’s protocol 
was explored in a pilot study by Williams et al.32 Dietary sodium restriction, as part of an 
intensive volume control strategy that involved slowly reducing post-dialysis weight by 200-
300g/treatment, resulted in a decrease in systolic BP in patients whose pre-dialysis systolic BPs 
were above 160mmHg. Additionally, IDWG was reduced in those whose pre-dialysis systolic BP 
was above 140mmHg. This data suggests that dietary sodium restriction is a valuable component 
of a comprehensive volume reduction strategy aimed at improving CV function.   
To date, only two randomized-controlled trials (RCTs) have assessed the lone effects of 
dietary sodium restriction in HD patients. First, Rodriguez-Telini et al.33 examined the effect of 
sodium restriction (prescribed reduction of 5g of salt/1,950mg of sodium per day) on BP, IDWG, 
and inflammatory markers. Although there was no change in BP or IDWG after 16 weeks, 
inflammatory markers (C-reactive protein, tumor necrosis factor alpha, and interleukin 6) were 
reduced by 54%, 64%, 56%, respectively in the sodium-restricted group, but no change in the 
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control group. However, the small sample size in this study (n=21 in sodium restricted group) 
suggests that additional studies are needed before definitive conclusions can be drawn. Finally, 
in the BalanceWise study, which aimed to assess the efficacy of a technology-supported 
behavioral intervention for dietary sodium restriction, Sevick et al. reported baseline dietary 
sodium intakes between 2,298±957 and 2,555±2,090 mg of sodium/day. After 8 weeks, patients 
in the intervention group reduced dietary sodium an average of 371mg/day, but these changes 
were not sustained at 16 weeks. Furthermore, there were no changes in IDWG at 8 or 16 
weeks.34 Despite the aforementioned potential benefits of dietary sodium restriction, more 
adequately-powered RCTs are needed to guide a specific recommendation in HD patients.  
Potential concerns with dietary sodium restriction  
In a recent review by Kalantar-Zadeh et al.,13 it was stated that sodium restriction may be 
beneficial as long as optimal nutritional status and food intake is not compromised. Indeed, 
malnutrition and the risk of protein-energy wasting are primary concerns with a sodium-
restricted diet due to the wide use of sodium in foods. Data supporting this concern was reported 
by Dong et al.,35 who found an association between low-dietary sodium intake and higher 
mortality25. However, these results should be interpreted with caution considering this was in a 
cohort of peritoneal dialysis patients. Furthermore, the average body-mass index was ~23 kg/m2 
and serum albumin concentrations were low across all sodium quartiles (~3.5g/dl), which 
suggests possible malnutrition among all participants in this study. By contrast, in the RCT by 
Rodrigues-Telini noted previously,33 patient’s sodium intake was reduced by 2g/d (baseline 
dietary sodium intake of 9.25g/d) for 16 weeks without a reduction in total caloric or protein 
intake. This demonstrates that a sodium-restricted diet with uncompromised energy and protein 
intakes may be achieved with adequate nutritional counseling.    
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Finally, an additional concern regarding dietary sodium restriction is the loss of residual 
renal function. Residual renal function has been associated with positive outcomes in HD 
including survival benefit.36 Additionally, the preservation of residual renal function has an 
important role in nutrition, in part due to a better control of K+ and phosphorus.37 In a 
retrospective study by Ozkahya et al.,38 loss of residual renal function was observed in nearly all 
patients after three years of implementation of Izmir’s volume reduction protocol. However, little 
information was provided regarding the percentage of patients that were anuric/oliguric at 
baseline, their average residual urine output, or how long it was before their residual urine output 
was lost. Because few patients maintain significant urine output long after initiating HD, it is 
impossible to determine if this loss of residual function was related to the dietary sodium 
restriction, volume reduction, or dialysis vintage. Furthermore, some antihypertensive 
medications (e.g., loop-diuretics and angiotensin-converting enzyme inhibitors) have been 
proposed to preserve residual renal function in HD patients,39 which were discontinued in the 
aforementioned study. Despite this, it should be noted that several factors impacting CV disease 
risk in HD patients, including BP, cardiothoracic index, and IDWG, improved in this study. This 
suggests that even if a loss of residual renal function is a manifestation of sodium restriction, the 
CV-related benefits may outweigh this potential concern. Studies that aim to assess the effect of 
dietary sodium restriction on residual renal function and clinical outcomes are needed.  
Limitations and barriers with dietary sodium restriction  
Dietary sodium is found ubiquitously in the western diet and is particularly excessive in 
processed foods. It has been estimated that 75% of dietary sodium in the United States diet 
comes from processed foods, 15% is added in food preparation as salt, and 10% is endogenous to 
foods.40 Due to the high proportion of sodium coming from processed foods, the concept of 
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“foods consumed away from home”, such as fast-food and full-service restaurants, being 
associated with unhealthy eating patterns has been reported in the general population.41 This 
concept, however, assumes that foods prepared and consumed at home are a healthier option. To 
examine this, we recently conducted a pilot study examining food’s point of purchase in 60 HD 
patients (56±14 years old, 62% male, 71% African American). On dialysis days, 75% of the 
dietary sodium came from grocery/convenience stores, while 15% and 5% of sodium came from 
fast-food restaurants and full-service restaurants, respectively. By contrast, on non-dialysis days, 
49% of dietary sodium came from grocery stores, 31% from full-service restaurants, and 14% 
from fast-food restaurants. Surprisingly, in this study, the ratio of sodium to kcal was similar 
from foods purchased at each location. This challenges the concept that healthier foods, at least 
in terms of sodium content, are consumed at home. This information may be helpful for renal 
dietitians for implementing nutritional education and counseling techniques focused on 
improving shopping skills and reading labels to limit major sources of dietary sodium.  
Salt-taste perception may represent an additional barrier to comply with sodium-restricted 
diets. Salt-taste perception has been reported to be altered in ESRD patients.42,43 Changes in taste 
acuity may occur with increased age and nutrient deficiencies, such as zinc.44 In addition, it may 
take up to three months to adjust to a low-sodium diet in healthy populations,45 with no 
difference reported in HD patients.46 Therefore, palate adjustment to low-sodium diets may 
represent a challenge to HD patients due to repeated exposure to foods high in dietary sodium, 
and an altered salt-taste acuity.  
Phosphate 
Hyperphosphatemia and its clinical management 
10 
 
Phosphate is the second most abundant mineral in the body, with 85% stored in bone and 
the other 15% in soft tissues, blood and extracellular fluid.47,48 Factors that influence phosphate 
metabolism have been reviewed elsewhere.49 Hyperphosphatemia, or serum phosphorus 
≥5.5mg/dl, is one component of chronic kidney disease- mineral and bone disorder (CKD-MBD) 
and its prevalence in HD patients is as high as 50%.50 Hyperphosphatemia has been associated 
with an increased risk of mortality,51 specifically from CV causes, where it may increase the risk 
vascular calcification and left-ventricular hypertrophy.52 CKD-MBD is also associated with 
decreased physical function, increased risk of fractures, and reduced quality of life.53 The current 
clinical management of hyperphosphatemia is focused on dialysis treatment, phosphate-binder 
therapy, and dietary phosphorus restriction.7,54 The efficiency with which phosphate is removed 
by dialysis and control of phosphate with phosphate binders have been reviewed elsewhere.55–57 
Dietary phosphorus restriction represents a cornerstone of the renal diet and the treatment of 
CKD-MBD. The recommended dietary phosphorus intake is less than 800 to 1000mg/day.7 
However, the efficacy of this recommendation has not been established. Furthermore, this 
restriction does not distinguish between types of dietary phosphorus, and in conjunction with 
dietary K+ restriction may lead to a lower intake of other nutrients, such as dietary fiber.8  
Types of dietary phosphate: focus on avoidance of phosphate additives 
Dietary phosphorus can be divided in two kinds: organic and inorganic. Organic 
phosphate is found mostly as phosphoproteins and membrane phospholipids in animal sources 
(e.g., meat and dairy) and as phytate in vegetable sources (e.g., legumes, whole grains and nuts). 
Animal sources have an absorption rate of 40% to 80%, being higher when vitamin D is 
present.58 Meanwhile, vegetable sources have an absorption rate of 20% to 40%58 because most 
of the phosphorus is found as part of phytate, which must be hydrolyzed by phytase to be 
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released and absorbed in the small intestine. Phytase, however, is not expressed in the small 
intestine; therefore, absorption of phytate-containing foods is even more limited. Vegetable 
sources containing yeast may have increased phosphate availability due to yeast phytase 
activity.59 Phosphate concentrations in both animal60 and vegetable sources61 also may be 
reduced with some cooking methods, such as boiling, slicing, and pressure cooking.   
By contrast, inorganic phosphate is not normally found in fresh/unprocessed foods. 
Instead, it is used as an additive in processed foods to increase palatability and shelf-life, among 
other reasons.58 Inorganic phosphate has an absorption rate of more than 90%, representing a 
major concern for HD patients.62 Consumption of phosphate additives has been estimated to be 
as high as 1000mg/day.40 However, it is difficult to precisely determine intake because the food 
industry is not required to report the quantity used in their products. Instead, they only need to 
list the additives in the ingredient list.62 This generally leads to an underestimation of dietary 
phosphorus intake, and represents a challenge to nutrition professionals when assessing patients’ 
intake. Recently, the Academy of Nutrition and Dietetics submitted a request to the Food and 
Drug Administration (FDA) to add dietary phosphorus to the nutrition facts panel and make a 
distinction between naturally-contained phosphate and phosphate additives.63 Unless this is 
adopted and enforced, assessing patients’ true phosphorus load and corresponding dietary 
prescriptions will remain a challenge.  
Liberalized organic phosphate restriction in HD patients  
Intensive nutritional counseling has been used by dietitians as a tool to reduce serum 
phosphate.64 The focus of the counseling sessions has evolved, from a phosphate restriction 
without a differentiation between organic and inorganic sources of phosphate, to a more recent 
focus on phosphate additives. This shift occurred due to a concern of low-protein and energy 
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intakes, which may lead to malnutrition and protein-energy wasting, and associated with lower 
physical function, reduced quality of life, and higher mortality.65 Furthermore, foods with only 
organic phosphorus typically are more nutrient-dense and have a higher nutritional value 
compared to processed foods containing phosphate additives, which tend to have a lower 
nutritional value, and are often paired with sodium and K+ additives.40 In a post- hoc analysis 
from the HEMO study, Lynch et al. found that phosphate restriction was not associated with 
improved survival, and was associated with a higher risk of mortality. Conversely, a more liberal 
phosphorus prescription tended to improve survival.66 Furthermore, Sullivan et al.67 found that 
by educating patients on how to avoid foods with phosphate additives by reading food labels and 
providing renal-friendly options at local fast-food restaurants, serum phosphorus decreased by 
0.6mg/dl compared to controls with standard dietary recommendations. Recently, a meta-
analysis by Karavetian et al.68 suggested that nutritional counseling based on a structured 
behavioral change may be successful in HD patients. However, only half of the studies reviewed 
were RCTs and most were short-term with a follow-up ranging from one to six months. 
Although more RCTs are needed to assess the efficacy of dietary phosphate restriction on 
hyperphosphatemia, nutritional education focused on restricting processed foods and cooking 
methods to reduce the availability of phosphate may benefit HD patients.  
Potassium 
Potassium (K+) is the main intracellular cation, which is important to maintain the cell’s 
membrane potential, heart function, nerve-impulse transmission, and skeletal muscle 
contraction.69,70 Regulation of serum K+ is an important concern for HD patients due to its effect 
on acute CV complications and mortality.70,71 In HD patients, the prevalence of hyperkalemia, 
defined as K+ ≥ 5.5 mmol/L, has been reported to be 4.5%-6.3%.70 Serum K+ levels are 
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influenced by many factors, including HD-related variables (blood and dialysate flow rate, 
dialysate K+ and buffer concentrations, dialysis length and efficiency), residual renal function, 
acid-base balance, fecal excretion, glucose metabolism, and shifts from intracellular 
compartments.72–74  
Current dietary guidelines for K+ in HD patients 
HD patients are recommended to restrict certain foods, such as fruits, vegetables, nuts, 
legumes, and dairy products that are high in K+70, primarily due to concerns with hyperkalemia. 
The KDOQI guidelines do not have a specific recommendation for dietary K+ for HD patients. 
However, the Joint Standards Task Force of the Academy of Nutrition and Dietetics and the 
National Kidney Foundation Council on Renal Nutrition recommend an intake of 2-4g/day.75 
However, there is little evidence to support these recommendations. In a cohort of 224 HD 
patients with 5-year follow-up, Noori et al.76 found that the association between dietary K+ 
(estimated by food-frequency questionnaire) and serum K+ was weak (r=0.14, p<0.05). 
Furthermore, St-Jules et al.77 found no association between dietary K+ intake and serum K+ in the 
BalanceWise Study cohort of 140 HD patients. Dietary K+ intake was positively associated with 
energy, protein and phosphorus intake, which have been associated with better outcomes in other 
large HD cohorts, such as the HEMO study.65,78 This suggests that dietary K+ restriction may be 
potentially deleterious if not implemented with caution in the face of increased risk of 
malnutrition and protein-energy wasting.76 Indeed, low K+ levels have also been associated with 
increased mortality in dialysis patients.71,79 Further studies are needed to assess whether the 
current restrictions on dietary K+ in HD patients are warranted.   
Alternative approaches to restricting dietary potassium 
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When restricting foods that naturally contain K+, other important nutrients are also 
restricted, such as dietary fiber. Indeed, dietary fiber intake in HD patients has been reported 
below the adequate intake of 25g/day for women and 38g/day for men.8,80 Fortunately, dietary 
K+ exposure can be limited using alternative cooking methods, such as boiling and leaching, 
particularly vegetables and legumes.81–83 Depending on the cut and pre-preparation steps, the 
amount of K+ loss can be reduced by as much as 75%.81 Moreover, K+ salts may be added to 
foods, such as meats, fish, dairy, and legumes, to enhance flavor or as a preservative.84 Sherman 
et al.85 compared the K+ content in a variety of enhanced and non-enhanced meat and poultry 
products and found that K+ levels averaged 8.7% higher in the enhanced products. The highest 
K+ concentration found in a non-enhanced product was 387mg K+ /100g, while the average K+ 
concentration in the top-five enhanced products analyzed was 692 mg/100g (max of 
930mg/100g). Moreover, some salt-substitutes are K+-based, containing an average of 600mg of 
K+ per ¼ teaspoon, potentially contributing to excessive dietary K+ load.75 Similar to 
phosphorus, dietary K+ is not required to be reported on the nutrition facts label of packaged 
foods and a recent study found K+ levels were included on less than 10% of the foods studied.86 
The addition of dietary K+ to nutrition fact labels has been recommended. If these changes are 
adopted, new labels should include total K+.84  
Because of these concerns, we propose an alternative approach to broad restrictions on 
high K+ foods for HD patients: 1) focus on limiting foods with added K+; and 2) liberalize the 
restriction on foods that naturally contain K+, while utilizing food preparation and cooking 
methods such as boiling and leaching to limit K+ intake, especially in vegetables and legumes. 
We recognize that some adjustments to this approach may be warranted for patients with overt 
hyperkalemia. However, since K+ is an intracellular ion, other causes should be also suspected, 
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such as inflammation, hemolysis, acidosis, as well as nutrition-related causes including poor 
appetite and low food intake that potentially promote muscle catabolism.77,87 A liberalized 
dietary approach for controlling K+ intake may have important health consequences for the 
majority of HD patients. Prospective studies using this approach are needed in addition to studies 
that aim to explore the efficacy of current practices, as well as the safety of this approach.  
Conclusion and Future Directions 
 It is well accepted that the HD dietary recommendations, namely to reduce the intake of 
sodium, phosphorus and K+, while increasing protein and total energy, may be confusing, 
counterintuitive, and thus difficult to follow. As a result, patient compliance with the renal diet is 
comprehensibly low.88 Based on the data presented herein, an alternative approach consisting of  
a simplified message focusing on dietary patterns to limit the intake of processed foods (from 
grocery/convenience stores, fast-food and full-service restaurants), enhancing patient’s self-
efficacy on how to shop and read nutrition fact labels, as well as promoting a whole-foods 
approach, may be warranted. We hypothesize that this approach will be associated with an 
overall decrease in IDWG and chronic volume overload, secondary to a decrease in overall 
dietary sodium, while supporting a dietary pattern consistent with lowered inorganic phosphorus 
and K+ additives, and increased fiber. This dietary pattern is likely to reduce risk factors for CV 
disease, the primary cause of death in HD patients.1 A similar dietary strategy, along with 
persistent volume reduction has consistently proven to significantly lower BP, nearly eliminate 
the need for antihypertensive medications, improve indices of cardiac structure and function, and 
reduce mortality rates in HD patients in Tassin31 and Izmir.38,89  
An added challenge to this approach is the need for patient and staff education. Intensive 
dietary counseling has been shown to improve nutritional markers such as serum albumin and 
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phosphorus,67 but renal dietitians lack the time to provide this level of patient interaction.90,91 
However, other members of HD clinic staff (nurses, social workers, technicians, and physicians) 
represent an underutilized opportunity for consistently reinforcing basic nutrition messages. 
Enlisting the support from the dialysis team may represent the best approach to achieve these 
food intake patterns without compromising energy and protein intake. The World Health 
Organization’s (WHO) Ottawa Charter states the need to create a supportive environment in 
order to empower patients and promote health.92 Additionally, family and/or caregivers should 
be included, since they are often responsible for handling food purchasing and preparation. 
Evidence that this approach can work in HD patients has been demonstrated by the data from 
Tassin31 and Izmir,38 as well as the studies by Krautzig et al.93 and Sullivan et al.,67 where the 
dietary message was based on simple recommendations, such as encourage home cooking, read 
food labels, avoid salt in food preparation, as well as obvious high-salt foods. Furthermore, these 
protocols have been structured to involve the entire dialysis clinic staff supporting the dietitians 
in helping counsel patients on how to lower their dietary sodium intake while maintaining an 
adequate nutritional status.31,89  
In contrast, in the United States the responsibility for nutritional counseling is usually 
guided by the renal dietitian with little support from the clinic staff.94 Dialysis providers in the 
United States have taken preliminary steps to remedy this with development of “Tech Talks”, 
which serve as talking points for dialysis technicians to utilize with patients. These “Tech Talks” 
consist of simple nutrition-focused messages aimed at decreasing phosphorus and sodium intake 
while increasing albumin; however, they are rarely utilized. Therefore, a simplified message 
focused on dietary patterns, led by renal dietitians, with support of the whole clinic staff, may 
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help improve patient’s overall diet in a manner that can help reduce chronic volume overload, 
CKD-MBD and enhance overall nutritional status and patient’s quality of life.   
Recommendations for Implementation 
Based on the concerns described above, we propose the following modifications to the 
dietary recommendations for HD patients (Table 2.1):   
1) Dietary restrictions on K+ and phosphorus from non-processed/whole foods should be largely 
eliminated. Specifically, few restrictions should be placed on fresh fruit, vegetables, nuts, 
legumes, and dairy products, as the health benefits associated with these foods likely outweigh 
the unsubstantiated risks attributed to them. This strategy will result in a shift from highly-
processed food products with added sodium, K+, and efficiently-absorbed inorganic phosphorus 
additives, to low-sodium foods with primarily poorly-absorbed organic sources of phosphorus 
that have the added benefits of additional antioxidants, vitamins, and dietary fiber. This 
recommendation should be taken within the context of clinical judgement and patient-specific 
considerations, particularly in terms of K+ intake. However, it is critically important to remember 
that little evidence exists in support of dietary K+ intake and hyperkalemia.77 Patients should also 
be instructed in food preparation methods known to reduce phosphorus and K+ quantities.   
2) Instead, the primary focus of dietary restrictions should be on the reduction/elimination of 
processed, restaurant, and convenience foods that are almost universally high in sodium, 
inorganic phosphorus, and added K+. Apart from these obvious benefits is the advantage of a far 
simplified message compared to current HD diet recommendations. Patients adhering to these 
recommendations may also realize cost-savings through increased food consumption within the 
home.  
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Implementing this approach will take a concerted effort focused on several factors. First, 
patient education must shift from providing lists of foods to not eat to instruction on how to 
identify and shop for unprocessed whole foods and label reading with an emphasis on sodium, 
K+, and phosphorus additives. One method that we have implemented in our counseling 
experience is to encourage patients to look for packaged products that have a sodium (mg) to 
kcal ratio of 1:1 or less. Products that contain fewer mg of sodium than kilocalories are generally 
lower sodium options and this concept is easily understood by patients. In addition, we firmly 
believe that HD clinic staff and caregiver support is essential to overall patient success. The 
clinic staff have the unique opportunity of extended face time with patients, allowing for 
consistent reinforcement of general nutrition principles. Caregiver support also is essential to 
ensure consistent messages and to eliminate a reversion to habits at home. This can be 
accomplished through continued staff and caregiver education alongside, and independent of, 
patient education. Development of staff and caregiver specific tools and resources may be 
necessary. Overall, improved patient health and quality of life may be within reach through a 
simplification and corresponding liberalization of the HD diet prescription. Further work must be 
conducted to establish protocols that are appropriate for implementation in the United States, 
taking into consideration HD treatment standards, the Western diet, and clinic staff education.  
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CHAPTER 3  
GUT MICROBIOTA AND CLINICAL RISK FACTORS IN HEMODIALYSIS 
PATIENTS  
Abstract  
The gut microbiota (GM) is important for human health and has been implicated in the 
pathogenesis of many chronic diseases. However, little is known about the composition and 
effects of the GM in patients with end-stage renal disease undergoing chronic hemodialysis 
(HD). The aim of this study was to examine the GM structure and its association with clinical 
risk factors in HD patients.  
Methods: In this cross-sectional study, ten HD patients (7M, 50 ± 4years, 80% African 
American) were assessed on a non-dialysis day. Assessment included: bone and body 
composition by DEXA; arterial function by applanation tonometry; dietary intake through 
dietary recalls over the 48h prior to the fecal sample collection; and plasma lipopolysaccharide-
binding protein (LBP). Participants were asked to collect a complete fecal sample; DNA was 
extracted and the V4 hypervariable region of the bacterial 16S rRNA gene was sequenced using 
Illumina MiSeq. Sequence data was analyzed using QIIME 1.9.1. Descriptive statistics were 
reported while Spearman correlations were used to compare GM operational taxonomic units 
(representative of ≥1% of total bacterial population) and clinical risk factors. 
Results: Firmicutes-to-Bacteroidetes ratio (1.40±0.37) was positively associated with resting 
brachial and aortic systolic blood pressures (ρ= 0.648 and 0.636, respectively; p<0.05). 
Additionally, it was positively associated with dietary intake of total and saturated fat (ρ=0.667 
and 0.636, respectively; p<0.05). At the genus level, Bacteroides was the most abundant genus in 
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all patients, ranging from 26.91% to 43.22% (mean 33.59±5.71%) of total sequences. 
Meanwhile, Faecalibacterium was variably represented between patients (median 7.54%; range 
0.1 to 23.17% of the total sequences) and was positively associated with total carbohydrate 
intake (ρ=0.636; p<0.05) and negatively associated with carotid-femoral pulse wave velocity 
(ρ=-0.867, p=0.001), a surrogate of arterial stiffness. LBP (32.35 ± 4.05µg/ml) was inversely 
associated with butyrate producers Ruminococcus and Roseburia (ρ=-0.733, -0.697, p=0.016, 
0.025, respectively) and positively associated with Bilophila, (ρ=0.644, p=0.044).  
Conclusions: The Firmicutes-to-Bacteroidetes was associated with traditional risk factors for 
cardiovascular disease. At the genera level, Faecalibacterium, was strongly associated with 
lower arterial stiffness, which is an independent risk factor for cardiovascular mortality in this 
population.  Finally, LBP was positively associated with Bilophila, and inversely associated with 
some genera that possess the enzymes necessary for butyrate production.  Future studies are 
needed to further explore the relationship between the gut microbiome and cardiovascular health 
in HD patients and to assess if interventions that target the gut microbiome translate into a lower 
burden for clinical risk factors in this clinical population 
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Introduction 
The gut microbiota is the community of microorganisms residing in the gut, including 
bacteria, archaea, viruses, and fungi.95,96 These microorganisms are especially concentrated in 
the distal ileum and throughout the colon.97 The gut microbiota is important for human health 
and has been implicated in the pathogenesis of many chronic diseases, including kidney 
disease.98 A unique gut microbiota has been described in chronic kidney disease (CKD) and end-
stage renal disease (ESRD), including bacterial overgrowth in the duodenum and jejunum, 
overgrowth of some aerobic species, such as Enterobacteria and Enterococci, and a decrease in 
commensal bacteria genera, such as Bifidobacteria.99,100  
Besides the gut microbiota composition, metabolites produced by these bacteria have 
been associated with cardiovascular disease and the progression of CKD.101,102 Specifically, p-
cresyl sulfate and indoxyl sulfate, which are products of the fermentation of tyrosine and 
tryptophan, respectively, have been associated with higher cardiovascular mortality, endothelial 
dysfunction, and mineral and bone disorder.103–106 Furthermore, trimethylamine-oxide (TMAO), 
which is derived from the bacterial metabolite trimethylamine through the metabolism of 
choline, betaine, and carnitine, has also been associated with the progression of CKD.99,104  
In healthy individuals these metabolites are excreted in the urine, but due to the reduced 
or blunted ability to produce urine in ESRD patients, the concentrations of these bacterial 
metabolites are higher than in adults with preserved kidney function.107–109  However, little is 
known about the structure of the gut microbiota and its relationship with clinical risk factors in 
ESRD patients undergoing maintenance hemodialysis (HD). Therefore, the objective of this 
study was to examine the gut microbiota composition and its association with clinical variables, 
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such as body composition, arterial stiffness, physical function, dietary intake, and blood 
biomarkers in HD patients.   
Methods 
HD patients were recruited from local dialysis clinics in Central Illinois. Patients were 
approached for recruitment if they received HD treatment 3 days/week, were ages >30 years, did 
not have gastrointestinal disease (e.g., inflammatory bowel disease), did not take antibiotic 
treatment the month before testing, and had been receiving dialysis treatment for at least three 
months. Consent was obtained from each participant and all protocols were approved by the 
University of Illinois Institutional Review Board and were in accordance with the Declaration of 
Helsinki.  
Following the initial recruitment, all individuals who qualified for the study and agree to 
participate underwent a battery of tests on a single occasion at the beginning of the study: 
Anthropometry, Bone, and Body Composition 
Barefoot standing height was measured to the nearest 0.1 cm with a stadiometer (Seca 
222, Hamburg, Germany). Body weight was measured on a digital scale (Tanita BWB-800, 
Arlington Heights, IL) with shoes and superfluous outer garments removed. All measurements 
were taken in duplicate and averaged. Whole-body fat, lean, bone mass, and bone mineral 
density was measured by dual emission x-ray absorptiometry (DXA) (Hologic QDR 4500A, 
Bedford, Massachusetts) following manufacturers protocol.   
Wave Reflection and Arterial Stiffness 
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Blood pressure was measured in duplicate using an automated cuff following a 10-minute 
quiet rest in the supine position (Omron IntelliSense HEM-907XL, Lake Forest, IL). Radial 
wave forms were then collected via tonometry and were used to estimate central pressures using 
a validated transfer function (SphygmoCor, AtCor Medical, Sydney, Australia). Aortic pulse 
wave velocity (PWV) was determined by tonometry (SphygmoCor, AtCor Medical, Sydney, 
Australia).110 In short, aortic PWV was calculated as the time delay (Δt) between the R-wave of 
the ECG and the foot of the forward pressure wave form (Intersecting Tangent) between the 
carotid and femoral arteries using the equation: PWV= D/Δt (m/sec); where D is distance in 
meters and Δt is the time interval in seconds. D was calculated by subtracting the distance 
between the sternal notch and the location the carotid pressure was measured from the distance 
between the sternal notch and the location the femoral pressure was measured. 
Physical Function  
Normal gait speed was determined as the average walking speed (meter per second) 
recorded over a 10-m course. The measurement was taken in triplicate and averaged. After the 
measurement of gait speed, participants underwent a validated  incremental shuttle walk test to 
assess physical performance as previously described.111 In short, this test involved walking back 
and forth over a 10-meter course to successively faster time constraints until the participant was 
no longer able to complete the course in the allotted time. Finally, participants completed the 8ft 
up-and-go test, in which starting in a seated position, participants are asked to walk as fast as 
possible to a mark (cone)placed 8ft apart and return back to their seat, to assess functional 
fitness.112   
Dietary Intake  
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Dietary recalls covering the 48 hours prior to receiving the fecal sample for analysis were 
collected by a trained researcher using the modified version of the USDA 5-pass method.113 In 
short, the first pass asks for the patients to recall everything they ate during the previous 24-
hours, the second pass probes for foods that may have been forgotten including beverages, 
snacks, and condiments, the third pass includes prompts for portion sizes and food amounts, the 
fourth pass asks for details about the food including brand names, and the fifth pass consists of a 
final review of the record. The records were analyzed for macronutrient and micronutrient 
composition, as well for food groups and individual food-item consumption using Nutrition Data 
System for Research (NDSR 2014 version, University of Minnesota, Minneapolis, MN).  
Fecal Collection and Consistency  
Participants were asked to collect a complete fecal sample (Commode Specimen 
Collection System Sage Products, Crystal Lake, IL).  Participants were asked to rate consistency 
and ease of passage for the bowel movement. Stool consistency was scored according to the 
Bristol Stool Scale. Ease of stool passage was ranked on a 5-point scale (1=very easy, 2=easy, 
3=neither easy nor difficult, 4=difficult, 5=very difficult). Samples were weighed, homogenized 
and three-2ml aliquots were stored at -80°C within 30 minutes of collection.  
DNA was extracted (Powerlyzer PowerSoil DNA Isolation Kit MO BIO, Carlsbald, CA) 
and its quantification was performed by Qubit Fluorometric Quantitation (ThermoFisher 
Scientific, Waltham, MA), while quality was assessed by electrophoresis with agarose 2% 
Agarose E-gels using the E-Gel iBase (Invitrogen, Grand Island, NY); primers targeting the V4 
hypervariable region of the bacterial 16S rRNA gene amplicons of 250bp were generated as 
described previously.114 Sequencing was performed through Illumina Mi-seq V3 platform. 
Relative changes in bacterial diversity (α-diversity) and taxonomical changes were analyzed 
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through the open software QIIME (version 1.9.1). In short, sequenced data was demultiplexed 
and went through quality filtering using split_libraries_fastq.py default parameters. Sequences 
were clustered into operational taxonomic units (OTU) using closed-reference OTU picking 
against the Greengenes 13_8 reference OTU database with a 97% similarity threshold.115  Since 
it was a cross-sectional study without a control group, α-diversity, or within-sample diversity 
was assessed through phylogenetic metrics (e.g., phylogenetic distance) and non-phylogenetic 
metrics (e.g., OTU count and Chao1).116 OTU count describes the number of OTUs in a given 
sample, whereas Chao1 takes into account the of rare species (i.e., singletons). Phylogenetic 
distance sums the branch length in a phylogenetic tree covered by the sample of interest.  
Blood chemistry   
Plasma samples were collected in lithium-heparin coated tubes at the start of the dialysis 
treatment immediately after the fecal sample collection.  Whole blood samples were centrifuged 
and separated into 500 µl aliquots and were stored at -80˚C until analyzed. A renal function 
panel that included albumin (bromocresol purple method), blood urea nitrogen, total calcium, 
chloride, creatinine, glucose, potassium, and sodium was measured by a point-of-care 
autoanalyzer (Piccolo Xpress, Abaxis Inc., Union City, CA).  
Lipopolysaccharide-binding protein (LBP) 
Plasma LBP was determined by a commercially-available enzyme-linked immunosorbent 
assay (ELISA) kit (Cell Sciences, Canton, MA). Inter-assay Coefficient Variation (CV) was 9.8-
17.8%, while the intra-assay CV was 6.1%. The effective range of the assay was 5-50 ng/ml. All 
standards, blank, and samples were performed in triplicate and averaged. If there was a percent 
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coefficient of variation (% CV) above 5%, the values were analyzed and assessed if one of the 
measurements should be deleted to decrease variation. 
Statistical Analysis  
All data were analyzed using SPSS 24 (IBM Corporation, Armonk, NY). Data are 
presented as the mean ± standard error of the mean (SEM), unless otherwise indicated. Spearman 
correlations were used to compare gut microbiota operational taxonomic units (representative of 
≥1% of total bacterial population) and variables of interest. For all statistical tests, significance 
was considered as p ≤ 0.05. 
Results 
In this cross-sectional study, ten HD patients (7 males/ 3 females, age 50 ± 4years, 80% 
African American, Table 3.1) were recruited and completed the assessments. For the fecal 
microbiota, a total of 308,536 bacterial 16S rRNA sequences were obtained, with a median of 
31,199 (range 25,056-35,617) sequences per sample. For diversity and species richness, the data 
was rarified to 25,056 sequences. We observed a mean species richness (Chao1) of 339±66 
species, which was inversely associated with age (ρ=-0.806; p=0.005) (Figure 3.2).   
At the phyla level (Figure 3.1), Firmicutes and Bacteroidetes were the most abundant, 
followed by Proteobacteria and Verrucomicrobia (54.02±1.53, 40.07±2.18, 2.63±0.59, and 
1.63±1.22% of total sequences, respectively). There was a Firmicutes-to-Bacteroidetes ratio of 
1.40±0.11, which was positively associated with traditional risk factors for cardiovascular 
disease, such as resting brachial and aortic systolic blood pressures (ρ= 0.648 and 0.636, 
respectively; p<0.05). Additionally, it was positively associated with dietary intake of total fat, 
saturated fat, and meat (ρ=0.667, 0.636, 0.661, respectively; p<0.05). At the genera level, 
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Bacteroides was the most abundant genus in all patients, with a mean of 33.59±1.81% of total 
sequences. Meanwhile, Faecalibacterium was variably represented between subjects (mean 
9.08±2.3% of total sequences; range 0.10-23.17% of total sequences) and was positively 
associated with total carbohydrate intake (ρ=0.636; p=0.048) and negatively associated with 
carotid-femoral pulse wave velocity (ρ=-0.867, p=0.001) (Figure 3.3). Concurrently, the genus 
Akkermansia was not present in 40% of the participants and its concentration ranged from 0 to 
12.02% of sequences (median 0.008%, interquartile range 0.0024-1.1081% of total sequences). 
Furthermore, Prevotella was only present in one participant, but was not associated with any 
variable tested. Other bacterial genera that have been associated with negative physiological 
effects were expressed in various relative abundances: Desulfovibrio (present in two subjects, 
1.41-1.51% of total sequences) and Bilophila (present in six subjects, 0.01-0.75% of total 
sequences), but no associations with any clinical risk factors were observed. Finally, LBP 
concentration was 32.35 ± 4.05 µg/ml, and was positively associated with Bilophila (ρ=0.644, 
p=0.044), and inversely correlated with Ruminococcus and Oscillospira. (ρ=-0.733, -0.697, 
p=0.016, 0.025, respectively).  
Discussion  
In this cross-sectional study, we assessed the relationship between the fecal microbiota 
and clinical variables of interest in ten HD patients. First, we observed that bacterial richness was 
inversely associated with age. At the phylum level, the two most abundant phyla were Firmicutes 
and Bacteroidetes. Furthermore, the Firmicutes-to-Bacteroidetes ratio was positively associated 
with traditional risk factors for cardiovascular disease, such as resting brachial and arterial 
systolic blood pressure, total fat and saturated fat intake, as well as meat intake. Moreover, 
plasma concentration of LBP, a marker of bacterial translocation, was positively associated with 
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Bilophila, and negatively associated with the known butyrate producing bacterial phyla 
Roseburia and Oscillospira, but not Faecalibacterium. Finally, and perhaps the most interesting 
finding, was that Faecalibacterium was associated with aortic pulse-wave velocity, a surrogate 
of arterial stiffness. Faecalibacterium prausnitzii is the most common species within the 
Faecalibacterium genus and it is a known butyrate producer.  
Bacterial species richness has been suggested as an important factor in the gut 
microbiome of healthy individuals.117 We observed a mean species richness of 339±66, which is 
below what has been reported in healthy adults and healthy elderly populations.118 Additionally, 
we found that species richness was inversely associated with age (Figure 3.2). These data 
support previous findings suggesting reduced species richness with age.9 Since CKD has been 
described as an accelerated aging process, we also assessed if there was a relationship between 
bacterial species richness and dialysis vintage. While no relation between these variables were 
found, this may have been due to the specifics of our study population, in which the younger 
patients tended to have spent more time on dialysis compared to older patients (<50y: 95±40 
months vs. 49±19 months). Previous studies have reported that species richness is lower in 
obesity.119 However, we did not find an association between species richness and body mass 
index or any other anthropometric measures, such as weight, whole-body fat, or waist-to-hip 
ratio.  
The ratio of Firmicutes-to-Bacteroidetes is commonly assessed in both healthy and 
clinical populations since these two phyla are the most abundant in the gut.120 In our study, 
Firmicutes were represented by 54.02±1.53% of the total sequences, while Bacteroidetes were 
represented by 40.07±2.19% of the total sequences, accounting for 94.09% of the total 
sequences. The Firmicutes-to-Bacteroidetes ratio has been reported to be greater in experimental 
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models of obesity, without a difference in food consumption, suggesting an increased capacity 
for energy harvest.121 However, several studies have found a higher ratio in lean individuals or 
did not agree with this association.122 In our study, the Firmicutes-to-Bacteroidetes ratio was 
1.40±0.37. Furthermore, we found a positive association between this bacterial ratio and intakes 
of total fat, saturated fat, and meat. This was somewhat surprising because a higher abundance of 
Bacteroides, a genera within the Bacteroidetes phylum, has been associated with an animal-
based diet, which is usually higher in total and saturated fat.123  Additionally, we did not find an 
association between Bacteroidetes phylum or Bacteroides genus and meat, fat, and saturated fat 
intake. Finally, we found no associations with other bacteria genera that traditionally have been 
associated with a higher consumption of animal-based products, such as Desulfovibrio and 
Bilophila. Larger scale studies should aim to assess the relationship between dietary patterns 
across CKD and changes in the gut microbiota structure and function.  
Interestingly, we found an inverse association between the genus Faecalibacterium and 
carotid-femoral pulse wave velocity, a surrogate of arterial stiffness. Within the genus 
Faecalibacterium, Faecalibacterium prausnitzii is a known butyrate producer.124,125 A decrease 
in this bacteria species has been reported with age.118  Concurrently, arterial stiffness increases 
with age.126 However, we did not find an association between Faecalibacterium and age. 
Interestingly, there have not been any reports of a direct relationship between the relative 
abundance of Faecalibacterium prausnitzii and cardiovascular disease. One possible explanation 
that may be driving this relationship is the inverse correlation between butyrate production and 
systemic inflammation.124 Unfortunately, we did not assess inflammation, which was a limitation 
of the study due to the link between the gut microbiota and immunity; the only indirect 
measurement of inflammation that we had available was albumin, which has been described as a 
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reverse acute-phase protein.  Nevertheless, this relationship was not significant (ρ=0.526; 
p=0.118). Further studies should aim to explore at a larger scale the relationship between 
Faecalibacterium prausnitzii and cardiovascular disease in CKD and ESRD.  
 Endotoxemia, or high concentrations of lipopolysaccharide (LPS) or proteins associated 
with it, such as LBP, have been reported prevalent in CKD and ESRD undergoing HD 
treatment.127 This may be in part due to the direct effect of uremia on the intestinal tight-junction 
proteins, increasing the risk of bacterial translocation from the intestinal lumen to the 
bloodstream.128 Moreover, endotoxemia contributes to the increased systemic inflammation in 
HD patients.129 In our study, we found that LBP was 32.35 ± 4.05µg/ml, which is higher than 
what has been reported in healthy subjects, but similar to other studies in CKD, ESRD, and 
kidney transplant subjects.127,130 LBP was inversely associated with Ruminococcus and 
Roseburia, genera with known butyrate producers, but not Faecalibacterium or other butyrate 
producers. Furthermore, we observed a positive correlation between LBP and Bilophila, which is 
a genus that has been associated with a dietary pattern high in animal products, such as meat.123 
However, we did not find an association between LBP and any nutrient intake or food group 
consumption. Future studies should aim to assess if interventions that target the gut microbiota in 
order to increase butyrate production decreases endotoxemia and inflammation in HD patients.  
 There are several limitations in our study. First, this was a cross-sectional study with a 
small sample size. Second, we did not have a control group to compare our variables against. 
Lastly, our patients were recruited from only one clinic in Central Illinois and cannot be 
generalized to other HD patients. However, we believe this study offers clear rationale to further 
explore the gut microbiota and clinical risk factors in HD patients and to develop targeted 
interventions to assess if changes in the gut microbiota translate into better outcomes in HD 
32 
 
patients, especially due to the association between the gut microbiota and cardiovascular disease, 
which is the main cause of mortality in HD patients.  
Conclusions 
We observed an inverse association of α-diversity with age, similar to what is reported in 
the aging population. Like other metabolic diseases, the gut microbiome showed a high 
Firmicutes-to-Bacteroidetes ratio at the phylum level. However, at the genus level there was 
high variability across individuals with some bacteria associated with positive health outcomes. 
Akkermansia, a gram-negative bacterium that preferentially colonizes the mucus layer and is 
associated with improved metabolic health, was expressed in relatively low concentrations and 
was not present in some individuals, similar to Prevotella, which previously has been associated 
with higher dietary fiber intake. This association, however, was not found because it was present 
in only one individual. In addition, dietary fiber intake was less than 50% of the recommendation 
(6.26±2.48g/1000kcal). Furthermore, Faecalibacterium, a known butyrate producer, was 
inversely correlated with arterial stiffness, an independent risk factor for cardiovascular mortality 
in this population. Finally, LBP was positively associated with Bilophila, and inversely 
associated with genera that possess the enzymes necessary for butyrate production.  Future 
studies are needed to further explore the relationship between the gut microbiome and 
cardiovascular health in HD patients and to assess if interventions that target the gut microbiome 
translate into a lower burden for clinical risk factors in this clinical population 
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Table 3.1 Patient characteristics 
Variable Mean ± SD /Median (IQR) 
Demographics 
     Age (years) 
     Sex (M/F) 
     Ethnicity (% African American) 
 
Anthropometry, bone, and body composition  
     BMI (kg/m2) 
     Waist-to-hip circumference ratio  
     Whole-body fat (%) 
     Whole-body lean mass (kg/m2) 
     Whole-body BMD (g/cm2) 
 
Cardiovascular 
     Brachial SBP (mmHg) 
     Brachial DBP (mmHg) 
     Aortic SBP (mmHg) 
     Aortic DBP (mmHg) 
     Augmentation Index @75bpm  
     cfPWV (m/s) 
 
Physical function  
     Gait speed (m/s) 
     ISWT (s) 
     8ft up-and-go (s) 
 
Dietary intake  
     Energy (kcal/kg/d) 
     Protein (g/kg/d) 
     Total fat (% total kcal) 
     Carbohydrates (% total kcal) 
     Fiber (g/1000kcal) 
     Protein-to-fiber ratio 
 
Blood parameters  
     Albumin (g/dl)  
     Phosphorus (mg/dl) 
     Potassium (mg/dl) 
     LBP (µg/mL) 
 
50 ± 4 
7/3 
80% 
 
 
31.04 ± 7.4 
0.94 ± 0.014 
30.21 ± 3.37 
21.09 ± 1.22 
1.2 ± 0.03 
 
 
157.3 ± 8.39 
82.3 ± 3.09 
143.6 ± 8.38 
84 ± 3.07 
28.3 ± 3.58 
9.21 ± 0.63 
 
 
9.06 (8.61-10.23) 
291.4 ± 44.05 
3.86 ± 0.82 
 
 
24.37 ± 2.77 
0.86 ± 0.09 
37.91 ± 2.39 
48.23 ± 2.53 
6.24 ± 0.79 
6.39 ± 0.57 
 
 
4.05 ± 0.09 
5.98 ± 0.58 
4.95 ± 0.18 
32.35 ± 4.05 
SEM, standard error of the mean (for normally distributed data); IQR, interquartile range for (for non-
normally distributed data); M, male; F, female; BMI, body mass index; BMD, bone mineral density; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minute; cfPWV, carotid-femoral 
pulse-wave velocity; ISWT, incremental shuttle-walk test; LBP, Lipopolysaccharide-binding protein. 
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Table 3.2 Relative abundance (% of total sequences) of bacteria (phyla and genera)   
Bacteria Genera  Mean ± SD /Median (IQR) 
Bacteroidetes 
     Bacteroides  
     Parabacteroides 
      
Firmicutes 
     Faecalibacterium      
     Lachnospiraceae 
     Clostridiales  
     Blautia 
     Ruminococcus 
     Dorea 
     Eubacterium      
     Streptococcus 
     Oscillospira 
     Roseburia 
 
Actinobacteria 
     Bifidobacterium 
 
Proteobacteria 
     Bilophila 
      
Verrucomicrobia 
     Akkermansia 
 
33.59±1.81 
4.66±1.14 
 
 
9.08±2.30 
5.80±1.02 
5.12±0.78 
4.68(1.52, 7.56) 
1.95(0.49, 4.34) 
1.53±0.45 
1.37±0.27 
0.94 ± 0.014 
0.59±0.12 
0.32(0.10,1.14) 
 
 
0.33(0.03,1.19) 
 
 
0.11(0.00,0.42) 
 
 
0.0081(0.0024,1.11) 
SEM, standard error of the mean (for normally-distributed data); IQR, interquartile range (for non-normally 
distributed data).  
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Figure 3.1  Firmicutes-to-Bacteroidetes ratio in HD patients 
Figure 3.1 Firmicutes and Bacteroidetes were the two most abundant phyla in our subjects 
and accounted for ~94% of the total sequences. The Firmicutes-to-Bacteroidetes ratio was 
1.4±0.37  
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Figure 3.1 There was a negative association between age and Chao1, a 
metric of α-diversity (ρ=-0.806, p=0.005) 
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Figure 3.2 There was a negative association between carotid-femora pulse 
wave velocity and the relative abundance of Faecalibacterium (ρ=-0.867, 
p=0.001). 
38 
 
CHAPTER 4 
EFFECT OF INULIN SUPPLEMENTATION ON MARKERS OF BONE AND 
MINERAL BIOMARKERS IN HEMODIALYSIS PATIENTS 
Abstract  
Mineral and bone disorder (MBD) is highly prevalent among hemodialysis patients (HD) and is 
associated with increased morbidity and mortality. Despite the pharmacological treatment for 
MBD, its prevalence remains high. The supplementation of dietary fiber may lead to an 
enhanced absorption of minerals mediated by the production of short-chain fatty acids (SCFA) 
by the gut microbiota, which has benefited other populations with MBD. However, this 
mechanism remains unexplored in HD patients. Our objective was to examine the effect of a 4-
week supplementation of a fermentable dietary fiber (inulin) on markers of mineral and bone 
metabolism and fecal excretion of minerals in HD patients. 
Methods: This was a randomized, double-blind, placebo-controlled, crossover design in which 
subjects consumed inulin (IN) [10g/d for females; 15g/d for males] or maltodextrin (CON) [6g/d 
for females; 9g/d for males] for 4 weeks, separated by a 4-week washout period. Plasma and 
fecal samples were obtained before and after each supplementation period. Blood chemistries 
were obtained using an autoanalyzer, while mineral and bone biomarkers were assessed using 
commercially available ELISA assays.  Outcomes were assessed using a within-subjects repeated 
measures ANOVA with treatment (IN, CON) and time (Pre, Post) as the independent variables.  
Results: Twelve HD patients completed the study (56±10 y, 50% male, 58% African American, 
31.2±9.2kg/m2). IN supplementation corrected dietary fiber intake (IN 7.9±5.3 to 
15.4±2.7g/1000kcal vs. CON 6.7±2.5 to 7.8±5.2g/1000kcal; p interaction=0.024). However, IN 
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did not produce any changes in blood calcium, phosphorus, and magnesium (p>0.05 for all), nor 
any of the biomarkers of bone and mineral metabolism of interest, including FGF-23, BALP, and 
CTX (p>0.05 for all). There was a time effect on iPTH, decreasing by 35% in both IN and CON 
groups (time p=0.031). Furthermore, there were no differences in the fecal excretion of calcium 
or magnesium (p>0.05). However, fecal excretion of phosphorus was maintained during IN 
supplementation (Pre 22.73±1.46 vs. Post 21.24±2.0, p=0.44), while it was decreased in the 
CON group (Pre 25.25±1.94 vs. Post 19.49±1.85; group-by-time interaction p=0.025), despite a 
similar phosphorus intake at both CON timepoints (Pre 914.96±134.72 vs. Post 
983.54±152.06mg/d, p=0.586).   
Conclusion: IN did not produce significant changes in plasma minerals or markers of bone 
metabolism, or fecal excretion of calcium and magnesium. Future studies should aim to explore 
whether isolated sources of fiber have an effect on the efficacy of phosphate binders and MBD 
markers in HD patients.   
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Introduction  
One of the most prevalent problems in ESRD patients undergoing chronic hemodialysis 
(HD) treatment is mineral and bone disorder (MBD), which manifests as early as chronic kidney 
disease (CKD) stage 2, where kidney function has declined by 10-40%.1,2 The diagnosis of MBD 
includes at least one of the following: a) laboratory abnormalities (e.g., hypocalcemia, 
hyperphosphatemia, secondary hyperparathyroidism, low concentrations vitamin D [calcidiol 
and/or calcitriol]) and high concentrations of fibroblast growth factor-23 (FGF-23); b) bone 
abnormalities (e.g., altered turnover, volume and mineralization); and c) extra-skeletal 
calcifications (e.g., vascular calcification).3 The disruption in bone and mineral homeostasis may 
critically affect bone structure and function by altering bone turnover, with a negative bone 
balance phenotype, characterized by a high bone resorption and normal-to-low bone formation.4 
Up to 80% of CKD patients have some degree of MBD, which has been associated with 
increased risk of fractures, cardiovascular disease, hospitalization and mortality and lower 
quality of life.5,6  
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend to 
monitor serum concentrations of calcium, phosphorus and parathyroid hormone (PTH). 
Recently, they recommended the addition of bone-specific alkaline phosphatase (BALP) as a 
confirmatory and complementary test to assess bone turnover.4 Furthermore, the National 
Kidney Foundation- Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines 
recommend pharmacological and nutritional therapies targeted to decrease MBD abnormalities 
in HD patients.7 Standard pharmacological therapies for MBD target a reduction in absorption of 
dietary phosphate (e.g., phosphate binders), mimic the action of calcium in the parathyroid gland 
(e.g., calcimimetics), and supplement vitamin D to offset its reduced activation by the kidney 
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(e.g., vitamin D analogues).3 Despite these therapies, it has been estimated that approximately 
50% of HD patients still have some degree of MBD.131 Furthermore, these therapies are 
expensive132 and may increase pill-burden,133 which is a major problem in HD patients. 
Therefore, low-cost therapies targeting improved bone and mineral metabolism are needed.  
Dietary phosphate restriction constitutes a vital part of the treatment for MBD along 
standard pharmacological treatment.7 For dialysis patients, the NKF-KDOQI guidelines 
recommend a dietary phosphate intake of 800-1000mg/day.7 This is in addition to restrictions on 
other nutrients, including potassium.94 To achieve this restriction, renal dietitians often advise 
HD patients to limit food groups that are high in these nutrients, such as fruits, vegetables, whole 
grains, nuts and legumes. However, these food groups are also good sources of dietary fiber, so 
their restriction may lead to a low fiber intake.8,134 Additionally, we have observed in a 
representative sample from our local dialysis units that patients consume less than 60% of the 
adequate intake (AI) of fiber, which is 14g/1000kcal or 25g and 38g/day for adult females and 
males, respectively.80 Recently, Chiavaroli et al.135 conducted a systematic review and meta-
analysis of the effect of supplementing dietary fiber on serum urea, creatinine, and phosphorus in 
CKD and ESRD patients. From the fourteen studies analyzed, they concluded that dietary fiber 
caused a significant decrease in urea (n=120; mean difference -4.9 (95% CI -8.4, 1.43) mg/dl), 
and creatinine (n=120; mean difference -0.25 (95% CI -0.47, -0.33) mg/dl), but not phosphorus 
(n=66; mean difference 0.12 (95% CI -0.22,0.49) mg/dl). The potential explanation for these 
effects include the effect of fermentable fiber on bacterial growth,136 displacement of protein as 
source of energy and use of it for growth,99 and the elevation of ammonium excretion due to a 
decreased pH through the production of SCFA.  This causes a shift from readily diffusible 
ammonia to less-diffusible ammonium.137  To date, the decrease on concentrations of creatinine 
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may be due to the expression of creatinase in some bacteria.138 Besides this study, there are no 
reports of the effect of fiber on mineral metabolism in CKD or ESRD patients.  
Dietary Fermentable Fibers: Inulin-type Fructans and Mineral Metabolism  
Dietary fiber is defined by the Food and Nutrition Board of the Institute of Medicine as 
those non-digestible carbohydrates and lignin that are intrinsic and intact in foods.139 
Additionally, they defined functional fiber as non-digestible carbohydrates that provide a 
beneficial physiologic effect, with the total fiber being the sum of dietary fiber and functional 
fiber.139 According to the dietary fiber’s physicochemical properties, they can be classified by 
their viscosity and fermentability properties, which also provide physiological benefits.140 In 
terms of fermentability, commensal bacterial in the distal ileum, but more importantly in the 
colon metabolize fibers partially or totally to hydrogen, methane, carbon dioxide and short-chain 
fatty acids (SCFA), such as acetate, propionate and butyrate.141 These SCFA have been shown to 
have effects locally (e.g., butyrate as energy source for colonocytes) and peripherally (e.g., 
adipose tissue, skeletal muscle, liver, brain, and kidney) by binding free-fatty acid receptors 
(FFAR) 2 and 3.142 Among dietary fermentable fibers, inulin-type fructans (ITFs) have been 
extensively studied in animal (Table 4.1), healthy populations, and clinical populations (Table 
4.2) due to their potential effect on mineral metabolism.  
Inulin is a plant-derived fermentable fiber (from chicory root and Jerusalem artichoke, 
principally) with β (2-1) fructosyl-fructose linkages. ITFs degree of polymerization ranges from 
2-70 fructose units with a low branching degree.143 However, those that have a degree of 
polymerization of 2-10 could also be named fructo-oligosaccharides and those with >10 subunits 
as inulin.141,143 Due to the β-linkages, ITFs cannot be hydrolyzed in the small intestine and, 
therefore, follow the criteria to be classified as a dietary fiber. In a review by Coxam,144 several 
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mechanisms were highlighted by which ITFs could improve mineral absorption. First, the 
bacteria in the distal gastrointestinal tract produces SCFA through the fermentation of ITFs. 
These SCFA in turn reduce the pH within the portion of the colon that are produced, improving 
the solubility of minerals (e.g., dissociating from other compounds, such as phosphates) and 
enhancing their absorption, especially through the paracellular route.145 Furthermore, butyrate is 
generally recognized as the major source of energy for colonocytes, and by enhancing its 
production, it enhances colonocyte growth and functional surface area for absorption. Finally, 
there is some indication from experimental models that transcellular absorption of calcium may 
also be increased after the supplementation of ITFs, mainly through vitamin D-dependent 
transporters (e.g., calbindin) and the enhanced hydrogen-calcium exchanger.144  
 Supplementation of ITFs has been used in animal models (Table 4.1) of MBD showing 
an enhanced calcium and magnesium absorption, contributing to mineral and bone homeostasis.  
Overall, an effect on fractional calcium absorption and retention has been shown across animal 
studies.  Effects in clinical populations (Table 4.2) also have been consistent, demonstrating up 
to a 12% increase in calcium absorption, as well as changes in bone turnover biomarkers. The 
effect of ITFs on mineral and bone metabolism in CKD and HD, however, has not been assessed.  
In a representative sample of our two dialysis clinics, 60.1% of patient’s had some 
alteration in markers of bone and mineral metabolism: 33.3% had hyperphosphatemia (serum 
phosphorus >5.5mg/dl), 68.6% had hyperparathyroidism (PTH >300ng/mL), and 17.5% had 
hypocalcemia (serum calcium concentrations corrected for serum albumin of <8.4mg/dl). 
Despite this high prevalence of MBD, the impact of supplementation of ITFs on mineral and 
bone homeostasis has not been documented in this clinical population. Therefore, our objective 
was to examine the changes in bone and mineral metabolism markers after a 4-week 
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supplementation of inulin. Our hypothesis was that four weeks of inulin supplementation would 
increase calcium and magnesium absorption, downregulating the secretion of parathyroid 
hormone (PTH) and decreasing the plasma concentration of phosphorus, compared to 
maltodextrin. Additionally, we tested the effect of the supplementation of inulin on bone 
turnover biomarkers: bone-specific alkaline phosphatase (BALP), as a marker of bone formation, 
and C-terminal telopeptide (CTX), as a marker of bone resorption.  
Methods 
HD patients were recruited from local dialysis clinics in Central Illinois. Inclusion criteria 
for participants included: 1) Received HD therapy 3 days per week and for at least 3 months. 
Exclusion criteria includes: 1) Sustained hypercalcemia (>3months). 2) Previous major 
gastrointestinal disease diagnosis (e.g., inflammatory bowel disease and celiac disease). 3) 
Antibiotic treatment less than two weeks prior the start of the study. 
Intervention Protocol 
As shown in Figure 4.1, in a randomized, placebo-controlled, cross-over design, patients 
were randomized to the intervention group (inulin [IN]) or placebo group (maltodextrin [CON]). 
For one month, patients consumed iso-caloric amounts of either: 1) IN (90% inulin with a degree 
of polymerization of 2-60 and 10% short-chain fructooligosaccharides, with a degree of 
polymerization of 2-8; ORAFTI SYNERGY, Beneo, Belgium) (IN; females: 10g/day; males: 
15g/day), or 2) CON (100% Maltodextrin, Now Foods Carbogain, Bloomingdale, IL) (females: 
6g/day; males: 9g/day).  Between treatment periods, all subjects underwent a four-week washout 
period before continuing with the other treatment (IN or CON) for another month. The first week 
of each intervention period was an adaptation week, in which patients consumed half of the dose 
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(5g/day and 7.5g/day for females and males, respectively in the IN group; 3g/day and 4.5g/day 
for females and males, respectively in the CON group).   
Supplementation Compliance 
 Supplement compliance was self-reported. Participants were asked at every HD treatment 
if they took the supplement that day and the previous day(s). Additionally, subjects were asked 
the type of fluid or food the supplement was mixed with, time of the day, and if the full or half 
dose was taken. Finally, bowel movement type was asked to be classified according to the 
Bristol Stool Chart at every HD treatment.  
Blood Minerals  
Blood samples (4ml) were obtained at the beginning and end of every period (Figure 4.1) 
during the HD treatment following the fecal sample collection (Chapter 5) in Lithium heparin-
coated tubes. Whole-blood calcium, magnesium, and serum phosphorus were measured using an 
auto-analyzer (MetLac12 panel, Piccolo-Xpress, Abaxis, Union City, CA). Calcium was 
corrected according to Obi et al.146 formula, which is specific for HD patients:  
𝐶𝑜𝑟𝑟. 𝐶𝑎 (
𝑚𝑔
𝑑𝑙⁄ ) = 1.35 × 𝑡𝑜𝑡𝑎𝑙 𝐶𝑎(
𝑚𝑔
𝑑𝑙⁄ ) − 0.65×𝐴𝑙𝑏(
𝑔
𝑑𝑙⁄ ) − 0.5×𝑃(
𝑚𝑔
𝑑𝑙⁄ ) + 0.3 
Where Ca is total calcium, Alb is albumin, and P is phosphorus.  
Fecal minerals  
 Participants were asked to collect a complete fecal sample (Commode Specimen 
Collection System Sage Products, Crystal Lake, IL) at the beginning and end of Period 1 and 2 
(Figure 4.1). Samples were weighed, homogenized, and stored at -80°C within 30 minutes of 
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collection until analysis. Fecal minerals (calcium, magnesium, and phosphorus) were assessed by 
atomic absorption spectroscopy and reported on a mg/g of dry matter basis.  
Intact PTH (iPTH) 
Plasma was collected in EDTA-coated tubes, then centrifuged at 2,400 rpm for fifteen 
minutes at 4°C, aliquoted and stored at -80°C until analysis. Intact PTH was measured by a 
commercially available enzyme-linked immunosorbent assay (ELISA) (ALPCO, Salem, NH). 
This assay had an intra-assay variability of 3.68-6.08% and inter-assay variability of 2.8-3.6%. 
The assay had a maximum detectable concentration of 1000 pg/ml. All standards, blank, and 
samples were performed in triplicate and averaged. Samples were diluted based on iPTH values 
from the patient’s clinical record of the month the samples were collected. If there was a percent 
coefficient of variation (% CV) above 5%, the values were analyzed and assessed if one of the 
measurements should be deleted to decrease variation. 
Fibroblast Growth Factor-23 (FGF-23) 
Plasma FGF-23 was measured by a commercially available ELISA kit (RayBiotech, 
Norcross, GA). This assay had an intra-assay variability of <10% and inter-assay variability of 
<12%. The assay had a detectable range from 300 to 100,000pg/ml. All standards, blank, and 
samples were performed in triplicate and averaged. If there was a percent coefficient of variation 
(% CV) above 5%, the values were analyzed and assessed if one of the measurements should be 
deleted to decrease variation. 
Bone-specific Alkaline Phosphatase (BALP) 
Plasma BALP was measured by a commercially available ELISA kit (BioTrend, Destin, 
FL). This assay had an intra-assay variability of <8% and inter-assay variability of <10%. The 
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assay had a detectable range from 3.12-200ng/ml. All standards, blank, and samples were 
performed in triplicate and averaged. If there was a percent coefficient of variation (% CV) 
above 5%, the values were analyzed and assessed if one of the measurements should be deleted 
to decrease variation. 
C-terminal Telopeptide (CTX) 
Plasma CTX was measured by a commercially available ELISA kit (NEO Scientific, 
Cambridge, MA). This assay had an intra-assay and inter-assay variability of <10%. The assay 
had a detectable range from 0 to 10ng/ml. All standards, blank, and samples were performed in 
triplicate and averaged. If there was a percent coefficient of variation (% CV) above 5%, the 
values were analyzed to assess if one of the measurements should be deleted to decrease 
variation. 
Bone and Mineral Metabolism Composite Score  
 We created a scoring system in which we classified our outcomes into positive, neutral, 
or negative, giving a value of +1, 0, or -1, respectively. Our scoring system was based on the 
expected concentration range of minerals and iPTH,3 previously reported significant effect on the 
FGF-23,147and expected positive/negative effect on the rest of the parameters (Figure 4.20).   
Body composition and bone mineral density 
Whole-body, lumbar spine, and hip scans were measured by dual emission x-ray 
absorptiometry (DXA) (Hologic QDR 4500A, Bedford, Massachusetts) following the 
manufacturer’s protocols. These measurements were used as descriptive variables and were 
performed only at baseline testing since we were not expecting changes in bone mineral density 
in a 4-week period.  
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Dietary intake  
Dietary recalls covering the 48 hours prior to receiving the fecal sample (Chapter 5) for 
analysis were collected by a trained researcher using the modified version of the USDA 5-pass 
method.113 In short, the first pass asks for the patients to recall everything they ate during the 
previous 24-hours, the second pass probes for foods that may have been forgotten including 
beverages, snacks, and condiments, the third pass includes prompts for portion sizes and food 
amounts, the fourth pass asks for details about the food including brand names, and the fifth pass 
consists of a final review of the record. The records were analyzed for macronutrient and 
micronutrient composition, as well for food groups and individual food-item consumption using 
Nutrition Data System for Research (NDSR 2014 version, University of Minnesota, 
Minneapolis, MN).  
Wave Reflection and Arterial Stiffness  
Blood pressure was measured in duplicate using an automated cuff following a 10-minute 
quiet rest in the supine position (Omron IntelliSense HEM-907XL, Lake Forest, IL). Radial 
wave forms were then collected via tonometry and were used to estimate central pressures using 
a validated transfer function (SphygmoCor, AtCor Medical, Sydney, Australia). Aortic pulse 
wave velocity (PWV) was determined by tonometry (SphygmoCor, AtCor Medical, Sydney, 
Australia).110 In short, aortic PWV was calculated as the time delay (Δt) between the R-wave of 
the ECG and the foot of the forward pressure wave form (Intersecting Tangent) between the 
carotid and femoral arteries using the equation: PWV= D/Δt (m/sec); where D is distance in 
meters and Δt is the time interval in seconds. D was calculated by subtracting the distance 
between the sternal notch and the location the carotid pressure was measured from the distance 
between the sternal notch and the location the femoral pressure was measured. These 
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measurements were performed in a subset of patients (n=5) during the same visit that the bone 
and body composition measurements were performed.  
Statistical Analysis  
 Mean and standard error of the mean is reported unless otherwise noted. Baseline subject 
characteristics were analyzed using a one-way ANOVA, where the grouping factor was sex and 
medications against the variable of interest (e.g., baseline blood minerals, bone biomarkers, etc.). 
Repeated measures ANOVA was performed in a within-subjects analysis with two groups (IN, 
CON) and two time-points (Pre, Post), comparing the variables of interest with significance at 
p<0.05. Pearson and Spearman’s correlations were performed between blood minerals, bone 
biomarkers, and other variables of interest. All statistical analysis was performed using SPSS 
version 24.  
Results 
 From the fifteen HD patients recruited, twelve patients finished the intervention, two 
patients dropped before starting the intervention, and one patient died (Figure 4.2). Patient 
baseline characteristics can be found in Table 4.3. At baseline, 33% had hypocalcemia (corrected 
calcium <8.2mg/dl), 50% had hyperphosphatemia (phosphorus ≥5.5mg/dl), and 83% had 
secondary hyperparathyroidism (iPTH ≥300pg/ml). Female subjects tended to have lower 
femoral neck bone mineral density (BMD) (female 0.705±0.07g/cm2 vs. male 0.922±0.037; 
p=0.019) and lower total hip BMD (female 0.827±0.49 vs. male 1.0417±0.089 g/cm2; p=0.051).  
Additionally, African American (AA) subjects had higher total hip BMD (AA 1.04±0.049 vs. 
Hispanic and non-Hispanic White 0.825±0.087g/cm2; p=0.045). Ninety-two percent of subjects 
were prescribed phosphate binders: 50% calcium-based phosphate binders (e.g., calcium 
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acetate), 50% non-calcium phosphate binders (e.g., sevelamer carbonate, sevelamer 
hydrochloride, and sucroferric oxyhydroxide), and one subject was prescribed one calcium and 
one non-calcium-based phosphate binder (calcium acetate and sucroferric oxyhydroxide). 
Additionally, phosphate binder prescriptions varied from one (sucroferric oxyhydroxide) to five 
(calcium acetate) pills per meal, with some patients having an additional recommendation for 
intake with snacks. Furthermore, fifty-eight percent of patients were prescribed a calcimimetic 
(e.g., cinacalcet), while 25% were prescribed vitamin D (e.g., cholecalciferol). Finally, patients 
that were prescribed a calcimimetic tended to have lower lumbar spine BMD (yes 0.95±0.059 vs 
no 1.16±0.043g/cm2; p=0.017), higher iPTH (yes 640.23±98.93 vs. no 222.62±25.05pg/ml; 
p=0.006), and lower BALP (yes 35.21±6.18 vs. no 79.55±46.18ng/ml; p=0.039).  
IN corrected dietary fiber intake (Pre 7.806±1.36 vs. Post 15.405±0.796 g/1000kcal, 
group-by-time interaction p=0.006) whereas in the CON group it was maintained (Pre 7.17±0.78 
vs. Post 7.58±1.21g/1000kcal) (Table 4.6). However, we did not observe any main effects or 
group-by-time interactions for blood calcium, phosphorus, and magnesium (p>0.05 for all) 
(Table 4.4, Figure 4.3-4.8). Additionally, IN did not produce any effects on FGF-23, BALP, or 
CTX-1 (Table 4.4, Figures 4.11-4.16). However, there was an iPTH time effect, where the 
concentrations decreased in IN and CON similarly by 34.95% and 34.60%, respectively (Table 
4.4, Figure 4.9-4.10). Furthermore, there was a numerical increase in phosphorus, FGF-23, and 
BALP after a 4-week consumption of inulin of 12%, 9.9%, and 9.96%, respectively, though 
these changes did not reach statistical significance (Table 4.4).  
Fecal excretion of calcium and magnesium did not differ after the supplementation of IN 
or CON (p>0.05) (Table 4.5, Figure 4.17 and 4.19). Concurrently, we assessed the dietary intake 
of minerals through dietary recalls of the 48h prior to the fecal sample collection.  Despite a 
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lower dietary calcium intake in the CON group (IN 775.35±88.29 vs. CON 600.76±69.50mg/d; 
group p=0.042), fecal calcium excretion was not different (Table 4.5). However, we observed a 
group-by-time interaction in the fecal excretion of phosphorus, where IN phosphorus excretion 
was maintained, while phosphorus excretion was lower after a 4-week supplementation with 
CON (Table 4.5, Figure 4.18). This may be explained by an overall lower phosphorus intake in 
the CON group (IN 1148.72±130.03 vs. CON 949.25±113.53mg/d; group p=0.043); however, 
the phosphorus intake at both CON time points were not different (Pre 914.96±134.72 vs. Post 
983.54±152.06mg/d, p=0.586). Nevertheless, it is important to highlight that the exact amount of 
dietary phosphorus consumed cannot be accurately assessed since current nutrition databases 
only report phosphorus that is naturally contained in foods, and not the amount that is used as 
phosphate additives.  
Finally, we designed a MBD Composite Score, in which we grouped the outcomes of 
interest (e.g., blood minerals, mineral and bone plasma biomarkers, and fecal excretion of 
calcium and phosphorus; Figure 4.20) to assess the effect of IN on MBD. In this composite 
score, a neutral (e.g., zero) or positive score is desirable. We observed that after a 4-week IN 
supplementation, subjects in the IN group were more likely to have a neutral or positive MBD 
Composite Score (IN 61.5% vs. CON 38.5%), though this difference did not reach statistical 
significance (p = 0.415). 
Discussion 
  In this randomized, placebo-controlled, cross-over design, IN corrected the low dietary 
fiber intake in HD patients. However, IN did not produce any changes in blood calcium, 
phosphorus, and magnesium, nor any of the biomarkers of bone and mineral metabolism of 
interest, including FGF-23, BALP, and CTX. Contrary to what we expected, iPTH change after a 
52 
 
4-week supplementation with IN and CON was very similar. Furthermore, there were no 
differences in the fecal excretion of calcium or magnesium. However, fecal excretion of 
phosphorus was maintained in the IN group, while it was decreased in the CON group, which 
may be explained by a lower phosphorus intake in the CON group.  Finally, intakes of energy, 
macronutrients, and minerals were maintained during the three months the study lasted.  
While there were no significant changes in our primary outcomes, it is important to 
mention that there were numerical increases in several markers, including blood phosphorus, 
FGF-23, and BALP after a 4-week supplementation with IN. Higher concentrations of 
phosphorus and FGF-23 have been associated with poor outcomes, including higher vascular 
calcifications,148 cardiovascular mortality,2,149 and overall mortality.6,150 Furthermore, although 
BALP is a marker of bone formation,4,151,152 it has also been associated with higher vascular 
calcifications.153,154 In the present study, we assessed the relationship between baseline 
concentrations of blood minerals, biomarkers of bone and mineral metabolism, and total hip, 
femoral neck, and lumbar spine bone mineral densities. However, we did not find any significant 
associations. Moreover, we assessed if there was relationship between carotid-femoral pulse 
wave velocity (cfPWV), a surrogate of arterial stiffness, and baseline blood minerals and bone 
and mineral metabolism biomarkers in a subset of our subjects (n=5). However, we did not find 
any significant associations, but our study was not powered to assess differences in markers of 
arterial stiffness.   
Our hypothesis was based on several studies in other populations with MBD, in which 
the supplementation of fermentable dietary fibers led to an increase in the absorption of calcium 
and magnesium. Calcium and magnesium absorption may be increased due to the fermentation 
of the supplemented dietary fibers, which yields SCFA and decreases the intracolonic pH.155 
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This decrease in pH may affect the solubility of intracolonic minerals, causing a dissociation 
from other minerals, and thus enhancing their absorption.155 However, most absorption of 
calcium and magnesium occurs within the proximal portions of the small intestine (duodenum 
and jejunum), with a small portion of these dietary minerals reaching the colon.69,156 In most of 
the studies in postmenopausal women and female adolescents, calcium and magnesium stable 
isotopes were used to assess fractional absorption rates. 157 However, in the present study, we 
used fecal excretion and plasma concentrations of minerals as a proxy to assess changes in 
absorption. We observed that, at a similar calcium and magnesium dietary intake, fecal excretion 
and plasma concentration of calcium and magnesium were not different after a 4-week 
supplementation with IN or CON.  
Dietary phosphorus is a mineral that theoretically would be more likely to reach the colon 
due to the use of binders to reduce phosphorus absorption in HD patients. Phosphorus binders are 
widely prescribed to reduce serum phosphorus and the negative outcomes associated with 
hyperphosphatemia, including increased vascular calcifications, all-cause mortality, and 
cardiovascular mortality.57,132 In present study, 92% of the subjects were prescribed phosphate 
binders: 50% calcium-based phosphate binders (calcium acetate), 42% non-calcium phosphate 
binders (sevelamer hydrochloride, sevelamer carbonate, and sucroferric oxyhydroxide), and one 
subject taking both types of phosphate binders (calcium acetate and sucroferric oxyhydroxide). 
The phosphorus-binding capacity differs between phosphate binders, where calcium acetate 
binds ~26.5mg/g, sevelamer hydrochloride/carbonate ~33mg/g, and sucroferric oxyhydroxide 
~240mg/g.158,159 Thus, by assuming patient’s compliance to their phosphate binder prescription 
and by knowing the number of meals and snacks that subjects consumed, we could calculate an 
approximate amount of dietary phosphorus that may have reached the colon. Although our 
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hypothesis was related to calcium and magnesium absorption, it may be possible that the pH 
reduction due to the fermentation of IN may have affected the solubility of phosphorus, 
ultimately reducing the efficacy of the binder, and increasing colonic phosphate absorption. 
However, we observed a lower fecal excretion of phosphorus only in the CON group. We would 
not expect to see an enhanced phosphorus absorption with CON because maltodextrin is a 
readily digestible carbohydrate. Future studies should aim to assess if isolated sources of fiber 
impact the solubility of phosphorus and thus decrease the efficacy of phosphate binders. If there 
is a reduction in the efficacy of phosphate binder therapy, the use of isolated sources of fiber may 
not be suitable for HD patients that are prescribed phosphate binders. Rather, an increase in 
dietary fiber through high-fiber foods and the effect on mineral metabolism should be explored.   
Due to the lack of an effect of IN on the individual parameters measured, we developed a 
composite score to collectively the impact of IN on all the MBD related measures (e.g., blood 
minerals, mineral and bone metabolism biomarkers, and fecal excretion of minerals).  Based on 
this MBD composite score, 23% more subjects had a neutral or positive value after IN, compared 
to CON, meaning that they had more MBD variables within a desirable concentration (e.g., 
blood minerals). This suggests that future studies should aim to assess if an overall improvement 
in markers of MBD translate into better outcomes in HD patients.  
There are several limitations to our study. First, we measured plasma minerals and 
mineral fecal excretion as a proxy for absorption instead of using stable isotope methodologies. 
Furthermore, we did not control for dietary intake prior to the specimen collection. However, 
there were no overall differences in dietary intake at the four timepoints. Moreover, the 
supplements’ compliance was assessed verbally every treatment, without any physiological 
measurement, such as breath hydrogen. Finally, our power analysis was based on data from other 
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clinical populations (e.g., postmenopausal women), in which the measurements were less 
variable than our population.  With the effect size seen on blood calcium (η2=0.016), we would 
have needed a sample size of 255 HD patients to observe an effect. Thus, it is likely that inulin 
may not influence blood minerals.  
Conclusion  
 IN did not cause a change in blood minerals and biomarkers related to mineral and bone 
metabolism, such as iPTH, FGF-23, BALP, and CTX. However, there was a ~10% increase in 
blood concentrations of phosphorus, FGF-23, and BALP. Furthermore, we did not observe any 
effects of IN on the fecal excretion of calcium and magnesium. However, after four weeks of 
CON, fecal excretion of phosphorus was lower. Future studies should aim to explore the effect 
that isolated sources of fiber have on the efficacy of phosphate binders and MBD markers in HD 
patients.   
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Table 4.1 Summary of supplementation of ITFs for bone and/or mineral metabolism in 
animal models   
 
Study Fiber Study Design Animal model Findings 
Legette 
2012160 
ITFs or PDX  1) AIN-93M 
control diet, 2) 
AIN-93M+ 5% 
ITFs (50-50% 
scFOS and lcFOS) 
3) AIN-93M diet+ 
ITFs (98% 
inulin+2% FOS) 
4) AIN-93M diet+ 
55% PDX for 4 
weeks 
5-month OVX 
Sprague-
Dawley rats 
(n=16 to 18 per 
group) 
ITFs ↑ Ca, SCFA 
and cecal wall 
weight.  
All fibers ↑Mg 
absorption.  
Naughton 
2011161 
Oligofructose-
enriched 
inulin 
1) AIN-93M 
2) AIN-93M + 
synbiotics (inulin 
1.44g/24h and 
Lactobacilus GG 
and 
Bifidobacterium 
lactis 3.96x1010 
CFU of each 
21-week and 
61-week old 
Sprague-
Dawley rats 
(n=16, 
respectively) 
↑ Ca concentration ↓ 
Osteocalcin in aged 
rats with synbiotics 
Varley 2010162 Inulin  1) low P  
2) low P + 20g/kg 
inulin 
3) high P 
4) high P + 20g/kg 
inulin  
Finisher pigs 
(n= total 40, 10 
per treatment) 
No effect in Ca and 
P digestibility or 
bone mineralization 
 
 
 
 
Coudray 
2005163 
Inulin 1) Control diet  
2) Control diet + 
3.75% inulin for 4 
days and then 
7.5% inulin for 3 
weeks 
2, 5, 10 and 20-
month Wistar 
rats (n= 8 per 
group) 
Inulin ↑ Ca and Mg 
absorption in all 4 
age groups. 
↑↑Ca absorption in 
aged rats 
Similar Mg 
absorption was in all 
groups 
 
Raschka 
2005164 
1:1 inulin and 
oligofructose  
1) Control diet 
(2% maltodextrin) 
2) Control diet 
+10% inulin-
oligofructose for 
21 days.  
Male Sprague-
Dawley rats 
(n=24 per 
treatment)  
↑ cecal contents, ↓ 
cecal pH 
↑total, soluble, and 
ionized Ca 
↑ surface area   
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Table 4.1 Cont.    
Coudray 
2005165 
Inulin Ca (0.25%, 0.50% 
or 0.75%) with or 
without inulin 5% 
during the first 4 
days and 10% for 
the rest: short-
term: day 13-17 
and long-term: day 
36-40 
10-week 
Wistar rats 
(n=10 per 
group) 
↑Ca and Mg 
absorption in the 
short and long term 
Ca absorption 
depended on Ca 
consumed  
Zafar 2004166 Inulin+FOS 1) AIN 93 
2) AIN 93 + inulin 
and FOS 55g/kg 
for 21 days 
6-month 
Sprague-
Dawley OVX 
rats (n=13 per 
group) 
↑ Ca absorption, 
femoral Ca content, 
BMD, and bone 
balance 
Bone resorption rate 
relative to formation 
was lower  
 
Kruger 2003167 FOS and 
inulin 
1) Semisynthetic 
diet with 0.5% Ca, 
2) same diet +5% 
FOS (DP 2-8)  
3) same diet + 5% 
inulin (DP>23)  
4) same diet + 5% 
inulin and FOS 
7-week old 
male Sprague-
Dawley rats 
(n=10 per 
group) 
↑ Femoral BMD 
femurs and spine 
BMC  
↓ CTx-1  
Coudray 
2003168 
FOS, inulin, 
branched-
chain inulin 
1) Purified diet, 2) 
same diet+ FOS, 3) 
same diet + inulin, 
4) same diet + 
inulin/FOS, 5) 
same diet + 
branched-chain 
inulin. First week 
2.5% fiber, second 
week 5% fiber, and 
third and fourth 
week 10%  
Male Wistar 
rats (n=10 per 
group) 
 
 
All fiber groups 
increased Mg 
absorption and 
balance. FOS/Inulin 
group increased Ca 
absorption and 
balance.  
Younes 
2001169 
Inulin and 
resistant 
starch  
1) fiber-free 
2) 100g/kg inulin 
3) 150g/kg potato 
resistant starch 
4) 50g/kg inulin 
and 75g/kg 
resistant starch.   
Adult male 
Wistar rats 
(n=8 per group) 
Both ↑ absorption of 
Ca and Mg, without 
changing plasma 
levels 
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Lopez 2000170 FOS 1) Fiber-free 
2) 100g/kg FOS 
3) 10g/kg phytic 
acid 
4) FOS+ phytic 
acid for 21 days 
Male Wistar 
rats (n=8 per 
group) 
FOS ↑ absorption by 
120% Ca, 150% Mg, 
123% Fe, 145% Cu. 
 Phytic acid ↓ 
absorption by 248% 
Fe, 262% Zn, 231% 
Cu, and affected 
plasma Mg  
FOS reduced this 
effects. 
Ohta 1998171 FOS 1) Gastrectomy + 
control diet 
2) Gastrectomy + 
75g/kg FOS 
3) Sham + control 
4) Sham + FOS 7d 
post-operation for 
25d.  
4-week 
Sprague- 
Dawley rats 
(n=14 per 
group)  
↑Ca absorption 
↑Ca absorption with 
FOS and prevented 
decrease in Ca 
content and BMD in 
gastrectomized rats 
Rémésy 
1993172 
Inulin 1) Fiber-free 
2) Fiber-free, 8g 
Ca/kg 
3) 15% inulin, 3g 
Ca/kg 
4) 15% inulin, 8g 
Ca/kg for 21d 
6-week male 
Wistar rats 
(n=12 per 
group) 
↑ cecum and 
fermentation profile 
↑ soluble Ca and P 
↑ Ca absorption was 
higher. 
ITFs, inulin-type fructans;OVX: ovariectomized, FOS: fructooligosaccharides, scFOS: short-
chain fructooligosaccharides, lcFOS: long-chain FOS, PDX: polydextrose, RM: resistant 
maltodextrin, RMH: hydrogenated resistant maltodextrin, Ca: calcium, Mg: magnesium, P: 
phosphorus, Fe: iron, Zn: zinc, Cu: copper, SCFA: short-chain fatty acids, CFU: colony forming 
units, E: experiment, BMD: bone mineral density, DP: degree of polymerization, 
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Table 4.2 Summary of supplementation of ITFs for bone and/or mineral metabolism in 
humans   
 
Study Fiber Study Design Clinical 
Population 
Findings 
Kruger 2015173 Ca and Vit D 
fortified milk 
with FOS-
inulin  
RCT:  
1) 2 glasses of 
regular (500mg of 
Ca)  
2) Fortified milk 
(1000mg for 
premenopausal and 
1200mg for 
postmenopausal 
women, 96mg Mg, 
2.4mg zinc, 15mcg 
vitamin D, 4g 
FOS) for 12 weeks.  
Premenopausal 
(41±5y, n=136) 
and 
postmenopausal 
(59±4y, n=121) 
females  
↓CTx-1 and PINP 
↓PTH  
Slevin 2014174 scFOS RCT: 
1) 800 mg of Ca 
2) 800 mg of Ca 
with 3.6 g of 
scFOS 
3) 9 g of 
maltodextrin. 
45-75-year-old 
postmenopausal 
women (n=300) 
↓CTX-1 at 12 
months  
↓osteocalcin at 24 
months in the Ca + 
scFOS group. 
 
Van den 
Heuvel 2009 
175 
scFOS  Randomized, 
double-blind, 
crossover design: 
1) 10g of scFOS  
2)Placebo 
(maltodextrin) for 
37d with washout 
period of 12 days 
12-14-year-old 
females (n=14) 
scFOS ↑ Mg 
absorption by 18% 
Abrams 
2007157 
ITFs 8g/day for 8wk 18-27yo healthy 
adults (n=13) 
In responders to the 
fiber (n=8), ↑ Ca 
absorption by ~9%  
Holloway 
2007176 
Oligofructose-
enriched 
inulin or 
maltodextrin 
(placebo) 
Double-blind, 
placebo-
controlled, cross-
over design.  
2 doses of 5g a day 
for 6 weeks 
Postmenopausal 
women (72±6y, 
n=15)  
↑Ca and Mg 
Responders tended 
to have ↓ lumbar 
spine BMD 
Abrams 
2005177 
Short and 
long-chain 
ITFs  
RCT, 8w and 1y 
follow up 
Pubertal 
adolescents 
(11±0.2y, ITFs  
n=48, control 
group n=50) 
↑ Ca absorption by 
8.5% higher at 8 
weeks and 5.9% at 1 
year  
BMC was higher 
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Table 4.2 Cont.    
Coudray 
1997178 
Inulin and 
sugar beet 
fiber 
3x3 Latin Square, 
28d periods, 18g of 
total fiber in 
control diet, and 
58g in the inulin 
and sugar beet fiber  
Male students 
(21±2y, n=9) 
Inulin ↑ Ca (12%), 
while sugar beet 
fiber increase Ca 
intake and balance, 
without a 
modification in Ca 
absorption.  
ITFs, inulin-type fructans;RCT: randomized-controlled trial, FOS: fructooligosaccharides, SCF: 
soluble corn fiber, GOS: galactooligosaccharides, scFOS: short-chain fructooligosaccharides, 
Ca: calcium, Mg: magnesium, BMD: bone mineral density, BMC: bone mineral content, CTx-1: 
C-terminal telopeptide of type I collagen, PINP: serum procollagen type 1N propeptide, PTH: 
parathyroid hormone. 
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Figure 4.1 Hemodialysis Inulin Trial was randomized, placebo-controlled, 
crossover study with a wash-out period of 4 weeks. At the beginning and end 
of each period, patients provided a fecal sample and the immediate HD 
treatment a blood sample was collected for the measurement of blood minerals 
and mineral metabolism biomarkers.  
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Table 4.3 Patient Characteristics   
Variable Mean ± SEM Reference Value 
Age (years) 
Gender (M/F) 
African American (%) 
BMI (kg/m2) 
Diabetes (%) 
Albumin (g/dl) 
  Corrected calcium (mg/dl) 
Phosphorus (mg/dl) 
Magnesium (mg/dl) 
Intact PTH (pg/ml) 
FGF-23 (pg/ml) 
BALP (ng/ml) 
CTX (ng/ml) 
56 ± 9 
6/6 
58.3% 
31.06 ± 2.58 
46% 
3.27 ± 0.27 
8.85 ± 1.32 
5.98 ± 1.54 
2.2 ± 0.3 
502.73 ± 301.52 
4321.64 ± 674.93 
53.69 ± 10.96 
3.81 ± 0.52 
N.A.  
N.A. 
N.A.  
18.5-24.9 
N.A.  
3.3-5.5 
8.0-10.3 
2.2-4.4 
1.6-2.3 
<300 
N.A. 
N.A. 
N.A 
SEM, standard error of the mean; N.A., not applicable; M, male; F, female; BMI, body mass 
index; PTH, parathyroid hormone; FGF-23, fibroblast-growth factor-23; BALP, bone-specific 
alkaline phosphatase; CTX, C-terminal Telopeptide 
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Figure 4.3 Plasma calcium concentration after 4 weeks with IN or CON  
 
 
Figure 4.3 Plasma calcium concentrations did not change after a 4-week 
supplementation with inulin (IN) or maltodextrin (CON).   
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Figure 4.4 Individual changes in plasma calcium after 4-weeks  
 
A. IN         
C
a
lc
iu
m
 (
m
g
/d
L
)
5
6
7
8
9
10
11
12
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Pre Post
B. CON  
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Hemodialysis patients show an inconsistent change in plasma calcium 
concentration after a 4-week supplementation with A. inulin (IN); and B. 
maltodextrin (CON).  
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Figure 4.5 There were no changes in plasma phosphorus concentrations after 
4 weeks with IN or CON 
Figure 4.5 Plasma phosphorus concentrations did not change after a 4-week 
supplementation with inulin (IN) or maltodextrin (CON).   
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Figure 4.6 Individual changes in plasma phosphorus after 4-weeks  
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Figure 4.6 Hemodialysis patients show an inconsistent change in plasma 
phosphorus concentration after a 4-week supplementation with A. inulin (IN); and 
B. maltodextrin (CON).  
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Figure 4.7 There were no changes in plasma magnesium concentrations after 
4 weeks with IN or CON 
Figure 4.7 Plasma magnesium concentrations did not change after a 4-week 
supplementation with inulin (IN) or maltodextrin (CON).   
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Figure 4.8 Individual changes in magnesium after 4-weeks with IN or CON 
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Figure 4.8 Hemodialysis patients show an inconsistent change in plasma 
magnesium concentration after a 4-week supplementation with A. inulin (IN); and 
B. maltodextrin (CON).  
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Figure 4.9 Plasma iPTH decrease is similar after 4 weeks of IN or CON  
* 
Figure 4.9 There was a time effect on intact parathyroid hormone (iPTH), decreasing to 
the same extent after a 4-week supplementation with inulin (IN) or maltodextrin (CON).  
* p time <0.05 
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Figure 4.10 Individual changes in iPTH after 4-weeks with IN or CON 
A. IN         
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Figure 4.10 Individual changes in intact parathyroid hormone (iPTH) after a 4-
week supplementation with A. inulin (IN); and B. maltodextrin (CON).  
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Figure 4.11 Plasma FGF-23 concentrations after 4-week supplementation with 
IN or CON  
Figure 4.11 No changes in fibroblast growth factor-23 (FGF-23) concentrations after 
a 4-week supplementation with inulin (IN) or maltodextrin (CON).  
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Figure 4.12 Individual changes in plasma FGF-23 after 4-weeks with IN or CON 
A. IN         
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Figure 4.12 Hemodialysis patients show an inconsistent change in plasma 
fibroblast growth factor-23 (FGF-23) concentration after a 4-week 
supplementation with A. inulin (IN); and B. maltodextrin (CON).  
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Figure 4.13 Plasma BALP after 4-week supplementation with IN or CON  
Figure 4.13 No changes in bone-specific alkaline phosphatase (BALP) concentrations 
after a 4-week supplementation with inulin (IN) or maltodextrin (CON).  
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Figure 4.14 Individual changes in BALP after 4-weeks with IN or CON 
A. IN         
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Figure 4.14 Hemodialysis patients show an inconsistent change in plasma bone-
specific alkaline phosphatase (BALP) concentration after a 4-week 
supplementation with A. inulin (IN); and B. maltodextrin (CON).  
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Figure 4.15 Plasma CTX after 4-weeks with IN or CON  
Figure 4.15 No changes in plasma C-telopeptide of type I collagen (CTX) 
concentrations after a 4-week supplementation with inulin (IN) or maltodextrin 
(CON).  
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Figure 4.16 Individual changes in CTX after 4-weeks with IN or CON 
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Figure 4.16 Hemodialysis patients show an inconsistent change in plasma c- 
telopeptide of type I collagen (CTX) concentration after a 4-week supplementation 
with A. inulin (IN); and B. maltodextrin (CON).  
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Figure 4.17 Fecal calcium excretion after 4-weeks with IN or CON  
Figure 4.17 No changes in the fecal excretion of calcium after a 4-week 
supplementation with inulin (IN) or maltodextrin (CON).  
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Figure 4.18 Fecal phosphorus excretion after 4-weeks with CON  
Figure 4.18 There was a group-by-time interaction on the fecal excretion of 
phosphorus, where it was reduced in the maltodextrin (CON), but not in the inulin 
(IN) group. * p interaction <0.05 
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Figure 4.19 Fecal magnesium excretion after 4-weeks with IN or CON  
Figure 4.19 No changes in the fecal excretion of magnesium after a 4-week 
supplementation with inulin (IN) or maltodextrin (CON).  
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Variable Negative (-1) Neutral (0) Positive (+1) 
Blood Calcium (mg/dl) 
 
 <8.2 
>10.2 
N.A.  8.2-10.2 
Blood Phosphorus (mg/dl) 
 
≥5.5 N.A. <5.5 
Blood Magnesium (mg/dl) 
 
<1.7 
≥2.2 
N.A.  1.7-2.1 
Plasma PTH (% change) 
 
↑25% -24 to 24% ↓25% 
Plasma FGF-23 (% change) 
 
↑25% -24 to 24% ↓25% 
Plasma BALP (% change) 
 
↓10% -9 to 9% ↑10% 
Plasma CTX (% change) 
 
↑10% -9 to 9% ↓10% 
Fecal Calcium (% change) 
 
↑10% -9 to 9% ↓10% 
Fecal Phosphorus (% change) ↓10% -9 to 9% ↑10% 
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Figure 4.20 MBD composite score after 4 weeks with IN or CON  
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Figure 4.20 Mineral and bone disorder (MBD) composite score based on blood 
minerals (calcium, phosphorus, and magnesium), biomarkers of mineral and bone 
metabolism (intact parathyroid hormone, fibroblast growth factor-23, bone-specific 
alkaline phosphatase, C-telopeptide of collagen type I), and fecal excretion of calcium 
and magnesium. A neutral (zero) or positive score denotes that most of the 
measurements were the values desired or had a desired % change (Table 4.3). A 
negative score denotes that most of the measurements are not on the values desired or 
an undesired % change after a 4-week supplementation with inulin (IN) or 
maltodextrin (CON). The subjects are on the x-axis. If a bar is missing for a treatment 
(IN or CON), the value is zero.  
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CHAPTER 5 
EFFECT OF INULIN SUPPLEMENTATION ON THE GUT MICROBIOTA 
STRUCTURE AND GUT MICROBIOTA-DERIVED METABOLITES IN 
HEMODIALYSIS PATIENTS 
Abstract 
Dietary fiber has been shown to alter the structure of the gut microbiota. Among dietary fibers, 
inulin-type fructans (ITFs) have been studied extensively due to its ability to modify the gut 
microbiota. In HD patients, ITFs have been supplemented and have been shown to be successful 
in reducing protein fermentation byproducts, such as p-cresyl sulfate. However, the effects of the 
supplementation of ITFs on the gut microbiome in HD has not been explored. Therefore, our 
objective was to assess the effect of a 4-week supplementation of inulin in the gut microbiota 
structure, fecal excretion of short-chain fatty acids (SCFA), protein-derived byproducts, and 
blood concentrations of microbial metabolites in HD patients.   
Methods: Twelve HD patients were recruited (56±10 y, 50% M, 58% African American, 
31.2±9.2kg/m2). In a randomized, double-blind, placebo-controlled, crossover design subjects 
consumed inulin (IN) [10g/d for females; 15g/d for males] or maltodextrin (CON) [6g/d for 
females; 9g/d for males]. Plasma and fecal samples were obtained before and after each 
supplementation period. DNA was extracted and the V4 hypervariable region of the bacterial 
16S rRNA gene was sequenced using Illumina MiSeq. Sequence data was analyzed using QIIME 
1.9.1. Fecal SCFA and protein byproducts were quantified by gas chromatography, while plasma 
metabolites by liquid chromatography-tandem mass spectrometry.  
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Results: In this randomized, placebo-controlled, cross-over design a 4-week supplementation of 
IN failed to show changes in the fecal microbiota α- and β-diversities, with no significant 
changes in gut bacteria at the phyla or genera level.  Both IN and CON caused an increase in the 
fecal excretion of acetate and propionate, with no effect on butyrate. However, there was a 
positive association between known genera with butyrate producers and fecal excretion of 
butyrate after supplementation with IN, but not CON. Similarly, there was a trend towards an 
association between the relative abundance of BCoAT and butyrate excretion after IN 
supplementation, but not CON. BCFAs and plasma metabolites derived from bacteria were 
unaffected after the supplementation of IN or CON. Finally, when we assessed the factors that 
explained the variability of the fecal microbiota in HD patients, sex, BMI category, and 
prescription of non-calcium-based phosphate binders revealed unique differences at the genera 
level.  
Conclusions: IN supplementation failed to show an effect on the gut microbiota structure. 
Furthermore, both acetate and propionate were increased after both supplementation periods, 
raising the question of digestibility of maltodextrin and its use as a control in HD patients. 
Despite a lack of effect of supplementation on butyrate, known butyrate-producing genera and 
BCoAT were positively associated with butyrate excretion after IN, but not CON. Interestingly, 
there was no effect of IN on uremic toxins derived from the gut microbiota. Finally, distinct 
microbiota structure was seen depending on sex, BMI, and use of calcium-based non-phosphate 
binders. Future studies should aim to study the long-term effects of IN supplementation on the 
gut microbiota structure and function and clinical outcomes in HD patients.  
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Introduction            
           The gut microbiota is the community of microorganisms that resides in the 
gastrointestinal tract, especially in the colon.95–97 The bacteria in the colon can utilize several 
carbohydrates that escaped digestion (dietary fiber) for energy production, such as resistant 
starches, cellulose, hemicellulose, glycogen, fructooligosaccharides, galactan, xylan, pectins, and 
gums.179 The amount of fiber in the diet has been shown to alter the structure of the gut 
microbiota.180 Diets high in dietary fiber have been associated with greater species diversity and 
a greater abundance of Prevotella, while animal-based diets  have been associated with greater 
abundance of Bacteroides.181  
          Among dietary fibers, inulin-type fructans (ITFs) have been studied extensively due to 
their ability to modify the gut microbiota.182 Inulin is a dietary fermentable fiber derived from 
plants (chicory root and Jerusalem artichoke, principally) with β (2-1) fructosyl-fructose 
linkages.143 Several bacteria genera have been shown to utilize ITFs, including Bifidobacteria, 
Lactobacillus, Bacteroides, and Faecalibacterium.125,183,184 Bifidobacteria has the ability to 
utilize ITFs due to the presence of exo-glycosidases, which hydrolyze monosaccharides at the 
non-reducing end of the oligosaccharide, and other enzymes to metabolize oligosaccharides 
intracellularly.185 Once the oligosaccharides are degraded to monosaccharides, these are 
converted to intermediates of the hexose fermentation pathway, which involves the pentose-
phosphate pathway, ultimately yielding lactate, acetate, and ATP.185  The lactate and acetate 
produced are then used by other bacteria for the production of butyrate, principally.186–188  
When there is a low dietary fiber intake, such as the one observed in hemodialysis (HD) 
patients,8 these bacteria may utilize other nutrients, such as protein that escaped digestion and 
absorption in the small intestine, but also endogenous compounds, such as sloughed intestinal 
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cells, mucin, hyaluronic acid, sialic acid and heparin.188–190 The fermentation of protein yields 
ammonia, branched-chain fatty acids, indoles and phenolic compounds, principally.187 These 
protein fermentation byproducts have been associated with higher cardiovascular mortality, 
endothelial dysfunction, and mineral and bone disorder in kidney disease.103–106 Furthermore, 
trimethylamine-oxide (TMAO), a metabolite derived from choline, betaine, and carnitine, has 
also been associated with the progression of CKD.99,104 In HD patients, ITFs have been 
supplemented and have been shown to be successful in reducing protein fermentation 
byproducts, such as p-cresyl sulfate.191 However, the effects of the supplementation of ITFs on 
the gut microbiome in HD has not been studied extensively in HD patients. Therefore, our 
objective was to assess the effect of a 4-week supplementation of inulin in the gut microbiota 
structure, fecal excretion of SCFA and protein-derived byproducts, and blood concentrations of 
microbial metabolites in HD patients.   
Methods 
HD patients were recruited from local dialysis clinics in Central Illinois. Inclusion criteria 
for participants included: 1) Received HD therapy 3 days per week and for at least 3 months. 
Exclusion criteria includes: 1) Sustained hypercalcemia (>3months). 2) Previous major 
gastrointestinal disease diagnosis (e.g., inflammatory bowel disease and celiac disease). 3) 
Antibiotic treatment less than two weeks prior the start of the study. 
Intervention Protocol 
As shown in the previous chapter (Figure 4.1), in a randomized, placebo-controlled, 
cross-over design, patients were randomized to the intervention group (inulin [IN]) or placebo 
group (maltodextrin [CON]). Patients consumed IN (90% inulin with a degree of polymerization 
of 2-60 and 10% short-chain fructooligosaccharides, with a degree of of 2-8; ORAFTI 
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SYNERGY, Beneo, Belgium) (IN; females: 10g/day; males: 15g/day) or CON (Now Foods 
Carbogain 100% maltodextrin, Bloomingdale, IL) (females: 6g/day; males: 9g/day) providing 
the same amount of energy for one month, underwent a two-week washout period, and continue 
with the other treatment (IN or CON) for another month. The first week of the intervention 
period was an adaptation week, in which patients consumed half of the dose (5g/day and 
7.5g/day for females and males, respectively in the IN group; 3g/day and 4.5g/day for females 
and males, respectively in the CON group).   
Fecal Sample Collection and Gastrointestinal Symptoms 
Participants were asked to collect a complete fecal sample (Commode Specimen 
Collection System Sage Products, Crystal Lake, IL) at the beginning and end of Period 1 and 2 
(Previous chapter Figure 4.1). Samples were weighed, homogenized and stored at -80°C within 
30 minutes of collection until analysis. Participants were also asked to rate consistency and ease 
of passage for the bowel movement. Stool consistency was scored according to the Bristol Stool 
Scale. Ease of stool passage was ranked on a 5-point scale (1=very easy, 2=easy, 3=neither easy 
nor difficult, 4=difficult, 5=very difficult). Samples were weighed, homogenized and three-2ml 
aliquots were stored at -80°C within 30 minutes of collection.  
DNA Extraction and Fecal Microbiota Analyses 
DNA was extracted (Powerlyzer PowerSoil DNA Isolation Kit MO BIO, Carlsbald, CA) 
and its quantification was performed by Qubit Fluorometric Quantitation (ThermoFisher 
Scientific, Waltham, MA), while quality was assessed by electrophoresis with agarose 2% 
Agarose E-gels using the E-Gel iBase (Invitrogen, Grand Island, NY). Primers targeting the V4 
hypervariable region of the bacterial 16S rRNA gene amplicons of 250bp were generated as 
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described previously.114 Sequencing was performed through Illumina Mi-seq V3 platform. 
Relative changes in bacterial diversity (α-diversity and β-diversity) and taxonomical changes 
were analyzed through the open software QIIME (version 1.9.1). In short, sequenced data was 
demultiplexed and went through quality filtering using split_libraries_fastq.py default 
parameters. Sequences were clustered into operational taxonomic units (OTU) using closed-
reference OTU picking against the Greengenes 13_8 reference OTU database with a 97% 
similarity threshold.115  For α- and β-diversity, samples were rarified to 67,614 
sequences/sample.  
Short-chain Fatty Acids, Branched-chain Fatty Acids, Total Phenols, and Total Indoles  
For the quantification of SCFA and branched-chain fatty acids (BCFA), a 2ml aliquot of 
the fecal sample was acidified with 2N-HCl (10% weight:volume) and frozen at -20°C until 
analysis, which was performed by gas chromatography . Fecal dry matter was measured 
according to the methods of the Association of Official Analytical Chemists and SCFA and 
BCFA, 192 phenols and indoles193 were measured as previously described.   
Plasma Metabolites 
Total plasma p-cresyl sulfate, indoxyl sulfate, and trimethylamine-oxide (TMAO) was 
measured by liquid chromatography-tandem mass spectrometry (UPLC-MS/MS method). The 
UPLC system was an Acquity H Class (Waters, Zellik, Belgium). Chromatographic separation 
was performed on an Acquity CSH Fluoro Phenyl column (50 x 2.5 mm; 1.7 mm particle size; 
Waters, Zellik, Belgium) with an Acquity CSH Fluoro Phenyl VanGuard pre-column (10 x 2.5 
mm; 1.7 mm particle size; Waters, Zellik, Belgium). The mobile phase, delivered at a flow rate 
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of 0.5 ml min-1 at 40°C, was a gradient of 0.1% formic acid in MQ water (A) and pure methanol 
(B) coupled to a Waters 2475 fluorescence detector, as described by de Loor et al.194  
Statistical Analysis  
Mean and standard error of the mean is reported unless otherwise noted. Repeated 
measures ANOVA was performed in a within-subjects analysis with two groups (IN, CON) and 
two time-points (Pre, Post), against variables of interest, such as alpha-diversity metrics, phyla 
and genera relative abundances, fecal excretion of metabolites, and plasma concentration of 
metabolites with significance at p<0.05.  Wilcoxon’s paired test was performed to assess any 
potential carryover effects (IN-Pre vs. CON-Pre) in the main variables of interest (e.g., 
Bifidobacterium, Faecalibacterium, and fecal excretion of SCFA).182 Spearman’s correlations 
were performed between bacteria genera with a relative abundance ≥1% and fecal and blood 
microbial metabolites. Additionally, the relationship between the bacteria genera, fecal and blood 
microbial metabolites and variables from Chapter 4 (e.g., blood minerals and mineral and bone 
metabolism biomarkers) were assessed. All statistical analysis was performed using SPSS 
version 24. Further statistical analysis was performed through Statistical Analysis of 
Metagenomic Profiles (STAMP) using categorical variables (e.g., IN vs CON [post-
supplementation only], sex, body-mass index [BMI] category, etc.). Analysis in STAMP was 
corrected for multiple comparisons using Benjamini-Hochberg False Discovery Rate (FDR).195  
Results 
Fecal microbiota α-diversity, β-diversity, and taxonomical analyses  
Twelve HD patients (56±10 y, 50% M, 58% African American, 31.2±9.2kg/m2) 
completed the study. For the fecal microbiota, a total of 4,411,326 bacterial 16S rRNA sequences 
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were obtained, with a median of 90,240 (range 67,614-146,384) sequences per sample. For α-
diversity or species richness, the data was rarified to 67,614 sequences. We did not observe 
changes in non-phylogenetic metrics of species richness after the supplementation of IN or CON 
(Chao1 IN Pre 372.26±9.56 species, Post 364.96±13.44 species vs. CON Pre 374.55±12.72, Post 
370.15.17 species; p>0.05). Additionally, we did not observe any difference in phylogenetic 
distance (PD), a phylogenetic metric of α-diversity, but there was a trend towards a time effect 
(INs Pre 24.72±0.89 vs. Post 24.12±0.99 and CON Pre 25.18±1.05 vs. Post 24.37±1.06, time 
p=0.093).  
For β-diversity, principal coordinates analyses (PCoA) of unweighted and weighted 
UniFrac performed on the 97% OTU abundance distance matrix failed to show differences or 
separation between treatments, time, or treatment-by-time (Figure 5.1). Furthermore, we 
observed that there was a low intra-individual variation in most subjects at all timepoints in the 
unweighted UniFrac PCoA, but a higher intra-individual variation in the weighted UniFrac 
PCoA, suggesting that there was a higher variation in the more abundant OTUs compared to the 
lower abundance OTUs after four weeks of IN or CON supplementation (Figure 5.2).  
At baseline, taxonomic analysis revealed that Firmicutes were the most abundant 
phylum, followed by Bacteroidetes, with a relative abundance of 64.01±2.58% and 27.56±2.73% 
of total sequences, respectively. Furthermore, the Firmicutes-to-Bacteroidetes ratio was 
2.68±0.36 (range 1.13-5.59). Bacteroides was the most abundant genera in the Bacteroidetes 
phylum and overall genera (Table 5.2). After the supplementation of IN or CON, there were no 
differences at the phyla or genera level (Table 5.2). Furthermore, we did not observe any 
differences in the genera of interest (e.g., Bifidobacterium or Faecalibacterium). However, there 
was a trend towards a time effect on Faecalibacterium, in which it increased after the 
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supplementation of IN and CON (IN Pre 5.77±1.45 vs. Post 9.24±2.05 and CON Pre 6.96±1.71 
vs. Post 8.42±2.28; p=0.079) (Table 5.2).  
Demographic variables determine gut microbiota structure  
 Principal components analysis (PCA) revealed a distinct fecal microbiota in female and 
male subjects (Figure 5.3 A). Additionally, there were specific differences at the genera level, 
where female participants had lower relative abundance of Faecalibacterium (FDR-corrected 
p<0.001) and higher Ruminococcaceae (FDR-corrected p=0.03) and Akkermansia (FDR-
corrected p=0.048) (Figure 5.3 B). Similarly, the fecal microbiota was different depending on 
body mass index (BMI) category, where subjects with a BMI <25 kg/m2 clustered together, as 
well as subjects with a BMI ≥30 kg/m2 (Figure 5.4 A). These differences were explained at the 
genera level, where Ruminococcaceae (FDR-corrected p=0.00291), Ruminococcus (FDR-
corrected p=0.025), Erysipelotrichaceae (FDR-corrected p=0.027), Lachnospira (FDR-corrected 
p=0.035), and Clostridium (FDR-corrected p=0.037) had a higher relative abundance in the 
subjects with BMI ≥30 kg/m2, compared to subjects with BMI <25 kg/m2 (Figure 5.4 B).  
Fecal excretion of SCFA and their relationship with the fecal microbiota  
Fecal excretion of SCFA was analyzed in only nine out of the twelve subjects that 
completed the study because we did not obtain the samples within one hour of fecal sample 
collection. For fecal excretion of SCFA, there was a time effect for the excretion of acetate and 
propionate, but not butyrate (acetate pre 219.48±39.31 vs. post 298.47±47.41 umol/g of dry 
matter (DM), time p=0.032; propionate pre 70.29±13.27 vs. post 89.74±15.33 umol/g DM time 
p=0.027; butyrate pre 40.89±8.05 vs. post 54.58±11.36 umol/g DM, time p=0.12) and a trend 
towards a group effect for butyrate (IN 43.10±9.19 umol/g DM vs. CON 52.37±9.34 umol/g 
102 
 
DM, p=0.075), but no treatment by time interactions (Table 5.3, Figure 5.5). Additionally, there 
were no changes in the molar ratios of the three SCFA in both periods (p>0.05). Total SCFA 
fecal excretion was not different between treatments, but there was a time effect (pre 
330.67±58.54umol/g DM vs. post 442.79±68.18umol/g DM; time p=0.03), with no carryover 
effect for those that were randomized to IN first (p=0.141). In terms of percent change, acetate, 
propionate, and butyrate increased after both treatments and we did not find significant 
differences between treatments (acetate IN 39.80±17.67% vs. CON 59.07± 19.71%, p=0.322; 
propionate IN 30.39± 23.35% vs. CON 68.33± 26.17%, p=0.137; butyrate IN 67.39± 44.63% vs. 
CON 72.51± 20.61%, p=0.886) (Figure 5.6).  
There was a positive association between the sum of genera with known butyrate 
producers (i.e., Clostridium, Lachnospiraceae, Coprococcus, Roseburia, Ruminococcus, 
Faecalibacterium, and Oscillospira) after IN supplementation and fecal excretion of butyrate 
(ρ=0.810; p=0.015), but not after CON supplementation (ρ=0.490; p=0.162) (Figure 5.7). 
Similarly, we found trend towards an association between the relative abundance of one of the 
bacterial enzymes needed for butyrate production, butyryl-CoA-acetyl-CoA transferase 
(BCoAT), and the fecal excretion of butyrate after IN supplementation (ρ=0.690; p=0.058), but 
not after CON supplementation (ρ=0.333; p=0.347) (Figure 5.8).  
Fecal excretion of BCFA  
Similar to SCFA fecal excretion, BCFA were measured in nine out of the twelve subjects. 
For fecal excretion of total BCFA, isobutyrate, isovalerate, and valerate we did not find any 
treatment effect, time effect, or treatment-by-time interactions (p>0.05, Table 5.3 and Figure 
5.9). However, when we considered the percent change after IN or CON, we observed a 
numerical increase in isobutyrate (IN 3.81±23.08% vs. CON 128.90±92.14%; p=0.173), 
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isovalerate (IN -4.41±21.05% vs. CON 422.59±373.99%; p=0.280), valerate (IN 2.48±20.77% 
vs. CON 109.90±87.02%; p=0.250), and total BCFA (IN -0.94±20.48% vs. CON 
169.40±131.73%; p=0.213), although these changes were not statistically significant (Figure 
5.10).  
Fecal excretion of phenols and indoles  
We did not observe differences in the fecal excretion of total phenols and total indoles 
after the supplementation of IN or CON (Table 5.3 and Figure 5.9). However, there was a trend 
towards a time effect on the fecal excretion of phenols (IN Pre. 260.01±49.88 umol/g DM vs. 
Post 158.28±50.87 umol/g DM and CON Pre 199.60±34.29 umol/g DM vs. Post 152.41±42.88 
umol/g DM; time p=0.051), but no effect on fecal excretion of indoles (IN Pre 12.76±20.03 
umol/g DM vs. Post 176.12±45.37 umol/g DM and CON Pre 259.23±40.93 umol/g DM vs. Post 
230.87±44.71 umol/g DM; time p=0.664). Additionally, we did not observe differences between 
treatments when we considered percent change after IN or CON in the fecal excretion of total 
phenols (IN -23.30±31.02% vs. CON -26.45±14.43%, p=0.940) or total indoles (IN -
9.75±18.73% vs. CON 4.33±22.88%, p=0.560) (Figure 5.10).  
Bacteria-derived plasma metabolites and their relationship with fecal excretion of metabolites  
We did not observe any changes in the bacteria-derived plasma metabolites indoxyl 
sulfate, p-cresyl sulfate, TMAO, or phenylacetylglutamine after the supplementation of IN or 
CON (Table 5.4). When we considered the percent change after the supplementation of IN or 
CON, we only observed a trend towards significance in indoxyl sulfate (IN -9.89±8.56% vs. 
CON 8.52±8.99%, p=0.141), but not p-cresyl sulfate (IN -2.22±13.1% vs. CON -12.26± 5.19%, 
p=0.441), TMAO (IN 12.46±23.50% vs. CON 27.09±18.80%, p=0.591), or 
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phenylacetylglutamine (IN 0.89±15.62% vs. CON 14.27±14.94%, p=0.539) (Figure 5.11). We 
did not observe an association between indoxyl sulfate and fecal excretion of total indoles after 
IN supplementation (ρ=0.183; p=0.637) or CON supplementation (ρ=-0.070; p=0.829). 
Similarly, we did not observe an association between p-cresyl sulfate and fecal excretion of 
phenols after IN supplementation (ρ=0.552; p=0.123) or CON supplementation (ρ=0.483; 
p=0.112).  
Gut microbiota and mineral metabolism  
Principal component analysis revealed a unique microbiota in those patients that 
consumed non-calcium-based phosphate binders (e.g., sevelamer hydrochloride and sevelamer 
carbonate). At the genera level, this was associated with a higher relative abundance of 
Ruminococcaceae (FDR-corrected p=0.0003) and Clostridiales (FDR corrected p=0.00335), and 
a higher relative abundance of Bacteroides (FDR-corrected p=0.0002) (Figure 5.12). There were 
no other associations between blood minerals, plasma biomarkers of mineral and bone 
metabolism, and fecal excretion of minerals.  
Discussion 
In this randomized, placebo-controlled, cross-over design a 4-week supplementation of 
IN failed to show changes in the fecal microbiota α- and β-diversities, with no significant 
changes in gut bacteria at the phyla or genera level. Both, IN and CON had an increase in the 
fecal excretion of acetate and propionate, with no effect on butyrate. However, there was a 
positive association between known genera with butyrate producers and fecal excretion of 
butyrate after supplementation with IN, but not CON. Similarly, there was a strong trend towards 
an association between the relative abundance of BCoAT and butyrate excretion after IN 
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supplementation, but not CON. BCFAs and plasma metabolites derived from bacteria were 
unaffected after the supplementation of IN or CON. Finally, when we assessed the factors that 
explained the variability of the fecal microbiota in HD patients, sex, BMI category, and 
prescription of non-calcium-based phosphate binders revealed unique differences at the genera 
level.  
ITFs have been shown to modify the gut microbiota structure in healthy adults182,196 and 
other clinical populations, such as subjects with obesity197,198 and diabetes.199,200 Most studies 
have reported an increase in the relative abundance of Bifidobacterium at the genera level, but 
also butyrate producers, such as Faecalibacterium, Anaerostipes, and  Roseburia.182,196,198,201  In 
the present study, we did not observe an increase in the a priori genera of interest 
Bifidobacterium or Faecalibacterium. Failure to observe an effect on Bifidobacterium has been 
reported as a methodological flaw in 16S rRNA gene sequencing due to the low relative 
abundance of this genus,202 which in our subjects was 1.89±0.99% of total sequences throughout 
the study time points. Furthermore, even though we observed a numerical increase in the relative 
abundance of Faecalibacterium after IN, we did not find a group-by-time interaction compared 
to CON. Besides these genera, reductions in other genera have been reported, such as 
Bacteroides and Bilophila.182,198 In our study, however, we did not observe any change in those 
genera.  
We hypothesized that the supplementation of IN would increase the fecal excretion of 
SCFA, especially butyrate, compared to CON. ITFs are fermented in the colon to acetate and 
lactate by Bifidobacteria through the bifidogenic shunt, which are then used by other bacteria to 
produce other SCFA, especially butyrate.188,190,202,203 We observed a trend towards a time effect 
on butyrate, increasing similarly after IN and CON. Despite the lack of effect of IN on butyrate, 
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we found a positive association between genera with species capable of producing butyrate and 
butyrate excretion after IN, but not CON. Similarly, we found a positive association between the 
relative abundance of BCoAT, one of the main enzymes needed for the bacterial production of 
butyrate, only after IN.125 These data suggests that gut microbiota of HD patients is capable of 
degrading IN and produce butyrate.  
We observed a time effect in the fecal excretion of acetate and propionate, meaning that 
these SCFA were increased after the both supplements. In fact, when we looked into the percent 
change, we observed a numerically higher effect of CON in acetate and propionate fecal 
excretion. Even without an increase in the dietary fiber intake in the CON group, this increased 
of fecal excretion of acetate and propionate suggests that maltodextrin may be fermented by the 
colonic microbiota.  We chose to use maltodextrin as our control because it is a completely 
digestible carbohydrate used extensively as a control for fiber supplementation studies. 
Maltodextrin is composed by a mixture of amylose and amylopectin, which have α(1-4) and α(1-
6) glycosidic bonds, respectively.204 Maltodextrin digestion starts in the mouth by the action of 
salivary α-amylose and continues in the proximal small intestine by the action of the pancreatic 
α-amylase to yield maltose, which then is finally metabolized to glucose by the brush border 
membrane-enzyme maltase.69,204 Data regarding abnormalities in carbohydrate digestion in HD 
patients is scarce. In a study by el-Lakani et al.205 it was reported that dialysis patients had 
decreased activity of mucosal maltase and sucrase, but not lactase. However, they concluded that 
overall HD patients did not have carbohydrate malabsorption. Studies aiming to assess digestion 
abnormalities in end-stage renal disease patients are needed.  
Modulation of the gut microbiota to reduce the production of uremic toxins is a topic of 
significant interest to Nephrology. In a study by Meijers et al.191, the supplementation of 20g of 
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oligofructose-enriched inulin resulted in a 20% reduction in p-cresyl sulfate, without a change in 
indoxyl sulfate. In our study, we did not observe a difference in plasma p-cresyl sulfate or 
indoxyl sulfate. Furthermore, we did not observe a decrease in the fecal excretion of total 
phenols or indoles. It has been suggested that by lowering the ratio of dietary protein-to-dietary 
fiber, the production of these bacteria-derived uremic toxins may decrease.109 Despite a higher 
fiber intake and a sustained protein after IN supplementation we did not find a decrease in these 
uremic toxins. Furthermore, specific bacterial species within the Bacteroides genus, such as B. 
thetaiotaomicron and B. ovatus have been shown to express tryptophanase, the enzyme needed 
for the breakdown of tryptophan to indole, which then will be absorbed and sulfated in the liver 
for the production of indoxyl sulfate.206 We did not find an association between the genus 
Bacteroides and the plasma concentration of indoxyl sulfate. However, with our microbial 
analysis we were not able to assess bacterial species relative abundance. Further studies should 
aim to assess determinants related to the effectiveness of prebiotic fibers on the reduction of 
microbiota-derived uremic toxins.  
We observed that demographic variables, such as sex and BMI, had a strong effect on the 
gut microbiota. First, we found a sex effect, in which male subjects had a higher relative 
abundance of Faecalibacterium, whereas female participants had a higher relative abundance of 
Ruminococcaceae and Akkermansia. Similarly, Chen et al.207 studied the fecal microbiota of 
subjects from the Midwest and found that there were differences in the gut microbiota of males 
and females. Additionally, we found that the fecal microbiota was different depending on the 
BMI class, where people with a BMI ≥30 kg/m2 had a higher relative abundance of SCFA-
producing bacteria Ruminococcaceae, Ruminococcus, Erysipelotrichaceae, Lachnospira, 
Clostridium. This may suggest an energy harvesting effect of the gut microbiota of people with 
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obesity. Similarly, Chen et al.207 observed an effect of BMI on gut microbiota. However, it 
remains controversial if gut microbiota contributes to obesity or obesity may cause changes in 
gut microbiota.208,209 Due to the reverse epidemiology observed in late stages of CKD,210 
prospective studies should examine the effect of the gut microbiota structure and SCFA 
production on clinical outcomes in HD patients.  
Regarding mineral metabolism, we observed a unique gut microbiota in those subjects 
that were prescribed non-calcium-based phosphate binders (e.g., sevelamer hydrochloride or 
sevelamer carbonate). Interestingly, the use of these binders was associated with a higher relative 
abundance of Ruminococcaceae and Clostridiales. Sevelamer hydrochloride/carbonate is a 
polymer that may have the non-selective ability of bind molecules, such as p-cresyl sulfate and 
indoxyl sulfate.109 Interestingly, we also observed that people with prescription of sevelamer had 
a lower relative abundance of Bacteroides. As mentioned earlier, tryptophanase is expressed in 
some of the species within the genus Bacteroides, such as B. thetaiotaomiron and B. ovatus. 
Future studies should aim to study the effects of non-calcium based phosphate binders on the gut 
microbiota structure and function.   
There are several limitations in our study. First, we assessed supplement compliance 
verbally, without any biological measurement, such as breath hydrogen. Second, we were not 
powered to detect differences in the fecal excretion of SCFA and plasma bacteria-derived 
metabolites. Third, our placebo (maltodextrin) seemed to be acting as a dietary fiber, which may 
have limited our ability to detect an effect after IN supplementation. Finally, we only collected 
one fecal sample at each timepoint, which may have limited our ability to detect a more 
meaningful effect of our intervention. However, we believe our results are valuable as this is the 
first study using a prebiotic fiber to assess its effects on the gut microbiota in HD. 
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Conclusion 
IN did not produce any changes in the gut microbiota structure. However, acetate and 
propionate fecal excretion were both increased after four weeks of IN and CON.  Though we did 
not find a treatment-by-time effect on butyrate excretion, we found a positive association 
between known genera with butyrate producers and butyrate excretion, as well as relative 
abundance of BCoAT and butyrate excretion after IN supplementation. Furthermore, IN did not 
produce a change in BCFA or plasma bacteria-derived metabolites. Finally, sex, BMI, and use of 
non-calcium-based phosphate binders showed differences in the gut microbiota structure of HD 
patients. Future studies should aim to study the long-term effects of IN supplementation on the 
gut microbiota structure and function and clinical outcomes in HD patients. 
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Table 5.1 Patient Baseline Characteristics  
Variable Mean ± SEM/ Median (IQR) 
Age (years) 
Gender (M/F) 
African American (%) 
BMI (kg/m2) 
Diabetes (%) 
Albumin (g/dl) 
Energy (kcal/kg/d) 
Protein (g/kg/d) 
Carbohydrates (% total kcal) 
Fat (% total kcal) 
Dietary Fiber (g/1000kcal) 
Acetate (umol/g DM) 
Propionate (umol/g DM) 
Butyrate (umol/g DM) 
Indoxyl Sulfate (uM) 
P-Cresyl Sulfate (uM) 
Trimethylamine N-Oxide (uM) 
56 ± 9 
6/6 
58.3% 
31.06 ± 8.62 
46% 
3.27 ± 0.27 
22.43 ± 3.14 
0.97 ± 0.14 
44.28 ± 2.01 
37.79 ± 1.77 
6.79 ± 0.85 
145.1 (103.53-254.62) 
57.92 ± 10.55 
35.63 ± 8.42 
110.65 ± 13.94 
180.82 ± 31.42 
58.97 ± 8.84 
SEM, standard error of the mean (for normally-distributed data); IQR, interquartile range (for 
non-normally distributed data); BMI; body mass index. 
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Figure 5.1 Unweighted and weighted Unifrac does not reveal any difference between 
treatment and time points 
 
A. Unweighted  
CON-
PRE 
CON-
POST 
IN-
PRE 
IN-
POST  
B. Weighted   
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Figure 5.1 Principal coordinate analysis (PCoA) of the unweighted (A) and 
unweighted (B) UniFrac performed on the 97% OTU abundance distance matrix does 
not reveal differences between groups (inulin and maltodextrin). Blue, Maltodextrin-
Pre; red, Maltodextrin-Post; green, Inulin-Pre; orange, Inulin-Post.  
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Figure 5.2 PCoA of unweighted and weighted Unifrac at the subject-level  
B. Weighted    
A. Unweighted    
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Figure 5.2 Principal coordinate analysis (PCoA) of the unweighted (A) and 
unweighted (B) UniFrac performed on the 97% OTU abundance distance matrix does 
reveals a low intra-individual variability within subjects. Every color denotes a 
different subject.   
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Figure 5.3 PCA plot reveals a different gut microbiota in female and male HD patients 
A.   
B.   
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Figure 5.3 Principal component analysis (PCA) performed on the 97% OTU 
abundance matrix reveals A. a unique microbiota for females and males. B. There was 
a higher relative abundance of Faecalibacterium in males (FDR-corrected p<0.001), 
and Akkermasia and Ruminococcaceae in females (FDR-corrected p=0.03 and 0.048, 
respectively). 
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Figure 5.4 PCA plot reveals a different microbiota in lean, overweight, and obese HD 
patients  
A. 
B. 
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Figure 5.4 Principal component analysis (PCA) performed on the 97% OTU 
abundance matrix. A. There was a unique microbiota in HD patients with BMI 
<25kg/m2 and ≥25kg/m2. B. There was a higher relative abundance of 
Ruminococcaceae, Ruminococcus, Erysipelotrichaceae, Lachnospira, and 
Clostridium in HD patients with obesity (FDR-corrected p=0.0029, 0.025, 0.027, 
0.035, 0.037, respectively).  
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Figure 5.5 Effect of inulin (IN) and maltodextrin (CON) on the fecal excretion of (A) acetate, 
(B) propionate, (C), butyrate, and (D) total short-chain fatty acids (SCFA). A. There was a 
time effect on acetate excretion. B. There was a time effect on propionate excretion. C. There 
was a trend towards a time effect on butyrate excretion. D. There was a time effect on total 
SCFA excretion. *p time <0.05. 
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Figure 5.6 Short-chain fatty acids are increased after 4-week of IN and CON, but there were no 
differences between treatments 
Figure 5.6 Percent change of acetate, propionate, and butyrate after a 4-week 
supplementation of inulin (IN) and maltodextrin (CON). All short-chain fatty acids were 
increased after IN and CON supplementation. After a paired t-test analysis, there was no 
difference between IN and CON.   
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Figure 5.7 There is a positive relationship between known butyrate producers and 
fecal butyrate excretion after IN supplementation, but not after CON  
A.  
ρ=0.810; p=0.015 
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Figure 5.8 There is a positive relationship between relative abundance of BCoAT 
and fecal butyrate excretion after IN supplementation, but not CON 
A.  
ρ=0.690; p=0.058 
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Figure 5.9 There were no effects of inulin (IN) or maltodextrin (CON) on the fecal excretion 
of (A) isobutyrate, (B) isovalerate, (C) valerate, and (D) total branched-chain fatty acids 
(BCFA).  
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Figure 5.10 There were no differences in the fecal excretion of BCFA after 4 
weeks with IN or CON  
Figure 5.10 Fold change of isobutyrate, isovalerate, and valerate after a 4-week 
supplementation of inulin (IN) and maltodextrin (CON). After a paired t-test analysis, there 
was no difference between IN and CON.   
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Figure 5.11 Change in microbial-derived plasma metabolites after 4 weeks of 
IN or CON  
Figure 5.11 Percent change of indoxyl sulfate, p-cresyl sulfate, trimethyl amine N-oxide 
(TMAO), and phenylacetylglutamine after a 4-week supplementation of inulin (IN) and 
maltodextrin (CON). After a paired t-test analysis, there was no difference between IN and 
CON.   
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Figure 5.12 PCA plot reveals an effect of non-calcium-based phosphate binders on the 
gut microbiota of HD patients   
A.  
B.  
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Figure 5.12 Principal component analysis (PCA) performed on the 97% OTU 
abundance matrix. A. There was a unique microbiota in HD patients that were 
prescribed non-calcium-based phosphate binders (e.g., sevelamer hydrochloride and 
sevelamer carbonate). B. There was a lower relative abundance of Bacteroides in those 
prescribed non-calcium-based phosphate binders (FDR-corrected p=0.00023) and a 
higher relative abundance of Ruminococcaceae and Clostridiales (FDR-corrected 
p=0.00032 and 0.00335, respectively).  
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CHAPTER 6 
FUTURE DIRECTIONS  
After our randomized, placebo-controlled, cross-over study, contrary to our hypotheses 
inulin supplementation in hemodialysis (HD) patients did not result in changes in biomarkers of 
mineral and bone metabolism, fecal excretion of minerals, or the gut microbiota. However, 
several factors may have affected our ability to observe the effects we hypothesized. First, the 
variability in the mineral and bone biomarkers was significantly more than what we expected 
and, therefore, our sample size may have been limited to observe any significant effects. For 
example, the effect size for blood calcium after inulin and maltodextrin was 0.016. After doing a 
post hoc power calculation, we would have needed 255 patients. Furthermore, our subjects were 
prescribed several medications (e.g., phosphate binders, calcimimetics, vitamin D analogs) that 
affect the mineral and bone metabolism biomarkers of interest. Therefore, the application of a 
similar approach in earlier stages of chronic kidney disease (CKD) may be more suitable since 
this patients may not be subject to the prescription of most of the medications aforementioned.  
Additionally, in earlier stages of CKD, inulin-type fructans may serve as a preventive therapy, 
rather than a treatment. Finally, as shown in Chapter 4, there have been several animal studies 
assessing the effects of inulin-type fructans on mineral absorption and mineral and bone 
metabolism biomarkers. However, to date, there have not been any studies on murine models of 
CKD, which represents an area of opportunity for future studies.  
Regarding the gut microbiome, we observed that demographic variables, such as sex, 
body mass index (BMI), and a diagnosis of diabetes were determinants of the gut microbiota 
structure. Additionally, we observed a different microbiota structure in those subjects that were 
prescribed non-calcium-based phosphate binders. This is particularly interesting because the 
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most widely used non-calcium-based phosphate binder (e.g., sevelamer hydrochloride/carbonate) 
may bind to other compounds in addition to phosphate, which may include uremic toxins 
produced by the colonic bacteria. Therefore, future studies should aim at examining the effects of 
these non-calcium-based phosphate binders on the gut microbiome structure and function.  
Finally, we decided to supplement fermentable fiber in an amount that represents about 
40% of the adequate intake (AI) of fiber for females and males. This was due to several studies 
reporting a low dietary fiber intake in hemodialysis patients,8,20 as well as previous studies 
performed in our laboratory (unpublished data). However, we did not recommend any changes in 
dietary intake or dietary patterns. Dietary patterns have shown to affect the gut microbiome, 
where subjects that consume a plant-based diet tend to have a different gut microbiota structure 
than those consuming an animal-based diet.180 HD patients have a very particular diet, in which 
they are recommended to increase their energy and protein intake, while limiting the 
consumption of sodium, potassium, and phosphorus. With these recommendations, patients may 
be led to consume low amounts of fruits, vegetables, whole grains, legumes, and nuts.211 These 
food groups, however, are good sources of dietary fiber. Nevertheless, the effect of current 
dietary patterns and a more liberalized diet in which patients may be able to consume more of the 
traditionally-restricted food groups and the effect on the gut microbiome and mineral metabolism 
has not been studied and should be explored in future studies.    
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